1
|
Kura K, Stolk WA, Basáñez MG, Collyer BS, de Vlas SJ, Diggle PJ, Gass K, Graham M, Hollingsworth TD, King JD, Krentel A, Anderson RM, Coffeng LE. How Does the Proportion of Never Treatment Influence the Success of Mass Drug Administration Programs for the Elimination of Lymphatic Filariasis? Clin Infect Dis 2024; 78:S93-S100. [PMID: 38662701 PMCID: PMC11045024 DOI: 10.1093/cid/ciae021] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/28/2024] Open
Abstract
BACKGROUND Mass drug administration (MDA) is the cornerstone for the elimination of lymphatic filariasis (LF). The proportion of the population that is never treated (NT) is a crucial determinant of whether this goal is achieved within reasonable time frames. METHODS Using 2 individual-based stochastic LF transmission models, we assess the maximum permissible level of NT for which the 1% microfilaremia (mf) prevalence threshold can be achieved (with 90% probability) within 10 years under different scenarios of annual MDA coverage, drug combination and transmission setting. RESULTS For Anopheles-transmission settings, we find that treating 80% of the eligible population annually with ivermectin + albendazole (IA) can achieve the 1% mf prevalence threshold within 10 years of annual treatment when baseline mf prevalence is 10%, as long as NT <10%. Higher proportions of NT are acceptable when more efficacious treatment regimens are used. For Culex-transmission settings with a low (5%) baseline mf prevalence and diethylcarbamazine + albendazole (DA) or ivermectin + diethylcarbamazine + albendazole (IDA) treatment, elimination can be reached if treatment coverage among eligibles is 80% or higher. For 10% baseline mf prevalence, the target can be achieved when the annual coverage is 80% and NT ≤15%. Higher infection prevalence or levels of NT would make achieving the target more difficult. CONCLUSIONS The proportion of people never treated in MDA programmes for LF can strongly influence the achievement of elimination and the impact of NT is greater in high transmission areas. This study provides a starting point for further development of criteria for the evaluation of NT.
Collapse
Affiliation(s)
- Klodeta Kura
- London Centre for Neglected Tropical Disease Research, London, United Kingdom
- Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, Imperial College London, London, United Kingdom
- MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, United Kingdom
| | - Wilma A Stolk
- Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Maria-Gloria Basáñez
- London Centre for Neglected Tropical Disease Research, London, United Kingdom
- Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, Imperial College London, London, United Kingdom
- MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, United Kingdom
| | - Benjamin S Collyer
- London Centre for Neglected Tropical Disease Research, London, United Kingdom
- Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, Imperial College London, London, United Kingdom
- MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, United Kingdom
| | - Sake J de Vlas
- Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Peter J Diggle
- Centre for Health Informatics, Computing and Statistics, Lancaster University, Lancaster, United Kingdom
| | - Katherine Gass
- Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia, USA
| | - Matthew Graham
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, United Kingdom
- Centre for Mathematical Modelling of Infectious Disease, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - T Déirdre Hollingsworth
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, United Kingdom
| | - Jonathan D King
- Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland
| | - Alison Krentel
- Bruyère Research Institute, Canada
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Canada
| | - Roy M Anderson
- London Centre for Neglected Tropical Disease Research, London, United Kingdom
- Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, Imperial College London, London, United Kingdom
- MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, United Kingdom
| | - Luc E Coffeng
- Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| |
Collapse
|
2
|
Sureshan M, Prabhu D, Rajamanikandan S, Saraboji K. Discovery of potent inhibitors targeting Glutathione S-transferase of Wuchereria bancrofti: a step toward the development of effective anti-filariasis drugs. Mol Divers 2024; 28:765-785. [PMID: 36797509 DOI: 10.1007/s11030-023-10617-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Accepted: 01/30/2023] [Indexed: 02/18/2023]
Abstract
Lymphatic filariasis (LF) is one of the major health problems for the human kind in developing countries including India. LF is caused by three major nematodes namely Wuchereria bancrofti, Brugia malayi, and Brugia timori. The recent statistics of World Health Organization (WHO) showed that 51 million people were affected and 863 million people from 47 countries around worldwide remain threatened by LF. Among them, 90% of the filarial infection was caused by the nematode W. bancrofti. Approved drugs were available for the treatment of LF but many of them developed drug resistance and no longer effective in all stages of the infection. In the current research work, we explored the Glutathione S-transferase (GST) of W. bancrofti, the key enzyme responsible for detoxification that catalyzes the conjugation of reduced GSH (glutathione) to xenobiotic compounds. Initially, we analyzed the stability of the WbGST through 200 ns MD simulation and further structure-based virtual screening approach was applied by targeting the substrate binding site to identify the potential leads from small molecule collection. The in silico ADMET profiles for the top-ranked hits were predicted and the predicted non-toxic lead molecules showed the highest docking score in the range of - 12.72 kcal/mol to - 11.97 kcal/mol. The cross docking of the identified hits with human GST revealed the potential binding specificity of the hits toward WbGST. Through WbGST-lead complex simulation, the lead molecules were observed to be stable and also intactly bound within the binding site of WbGST. Based on the computational results, the five predicted non-toxic molecules were selected for the in vitro assay. The molecules showed significant percentage of inhibition against the filarial worm Setaria digitata which is the commonly used model organism to evaluate the filarial activity. In addition, the molecules also showed better IC50 than the standard drug ivermectin. The identified lead molecules will lay a significant insight for the development of new drugs with higher specificity and lesser toxicity to control and treat filarial infections.
Collapse
Affiliation(s)
- Muthusamy Sureshan
- Department of Bioinformatics, Biomolecular Crystallography Lab, School of Chemical & Biotechnology, SASTRA Deemed University, Thanjavur, 613401, India
| | - Dhamodharan Prabhu
- Research and Development Wing, Sree Balaji Medical College and Hospital, Bharath Institute of Higher Education and Research, Chennai, 600 044, India
| | - Sundarraj Rajamanikandan
- Department of Biochemistry, Centre for Drug Discovery, Karpagam Academy of Higher Education, Coimbatore, 641021, India
| | - Kadhirvel Saraboji
- Department of Computational Sciences, Central University of Punjab, Bathinda, 151401, Punjab, India.
| |
Collapse
|
3
|
Njomo DW, Kimani BW, Kibe LW, Okoyo C, Omondi WP, Sultani HM. Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: Perceptions and experiences of community drug distributors of coastal Kenya. PLoS Negl Trop Dis 2020; 14:e0009012. [PMID: 33370300 PMCID: PMC7793263 DOI: 10.1371/journal.pntd.0009012] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2020] [Revised: 01/08/2021] [Accepted: 11/25/2020] [Indexed: 11/29/2022] Open
Abstract
Community drug distributors (CDDs) who are volunteers have the responsibility of awareness creation, household census, drug distribution and record-keeping and are thus key stakeholders in the campaign for Lymphatic Filariasis (LF) elimination. Taking into account their experiences and perceptions is important for a successful elimination campaign. We conducted a qualitative study in 2018 to identify implementation challenges and opportunities for improved mass drug administration (MDA) uptake based on the CDDs perceptions and experiences. Within a larger study that used mixed methods quasi-experimental design, we collected qualitative data from two wards in Kaloleni Sub-County of Kilifi County which was purposively selected owing to its low, 56% and 50.5% treatment coverage in 2015 and 2016 respectively. Focus group discussions (FGDs) (n = 8) and in-depth interviews (IDIs) (n = 8) with CDDs, IDIs (n = 22) with opinion leaders and IDIs (n = 8) with health workers were conducted and the data analyzed by QSR NVIVO version 10 according to thematic areas. The results showed that based on the perceptions and experiences of the CDDs, several challenges: communities’ refusal to take the drugs; absenteeism during MDA; non-adherence to CDDs selection criteria; inadequacy in number of CDDs engaged during the campaign and training provided; insufficiency of drugs issued to CDDs; lack of CDDs supervision and low motivation negatively impact on MDA uptake. Opportunities to address the challenges included: awareness creation on MDA, health education on LF and observation of hygiene during drug administration, increased duration of awareness creation and drug administration, adherence to CDDs selection criteria and putting into consideration the vastness of an area and population density while deploying CDDs. Other opportunities include: improved CDDs training and scheduling; issuing of enough drugs to CDDs to meet the communities’ demand and improved supervision and motivation of CDDs. Addressing the challenges highlighted is an important step of maximizing MDA uptake. The opportunities presented need to be considered by the NTD program personnel, the county health personnel and the community while planning the implementation of MDA campaigns. Elephantiasis infection which is common in tropical areas is targeted for elimination globally through delivery of drugs to all populations living in areas where infections occur. Community Drug Distributors (CDDs) are persons who live in the affected communities and who volunteer themselves to distribute drugs after receiving training from the health care workers. Understanding the challenges and opportunities for improved community drug uptake from the perspectives and experiences of the CDDs is important for a successful elimination campaign. As part of a larger study to address barriers of drug uptake in Kenya, we collected qualitative data to explore the challenges and opportunities for improved drug uptake in two wards of Kilifi County. The data was collected through focus group discussions and in-depth interviews and analyzed. For drug uptake to be improved, the CDDs’ mentioned challenges related to how their selection is done, number of CDDs engaged, quality of their training, quantities of drugs issued to them, supervision and motivation that need to be addressed. The communities targeted for treatment need well scheduled health education activities on elephantiasis, awareness creation on drug distribution and drug reaction for them to understand the importance of receiving the treatment. These findings suggest the need for strong collaborations between NTD program, county health personnel and the community that are useful in the planning the implementation of successful national programs.
Collapse
Affiliation(s)
- Doris W. Njomo
- Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC) Kenya Medical Research Institute (KEMRI), Nairobi, Kenya
- * E-mail: ,
| | - Bridget W. Kimani
- Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC) Kenya Medical Research Institute (KEMRI), Nairobi, Kenya
| | - Lydiah W. Kibe
- Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC) Kenya Medical Research Institute (KEMRI), Nairobi, Kenya
| | - Collins Okoyo
- Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC) Kenya Medical Research Institute (KEMRI), Nairobi, Kenya
| | - Wyckliff P. Omondi
- Division of Vector Borne and Neglected Tropical Diseases, Ministry of Health, Nairobi, Kenya
| | - Hadley M. Sultani
- Division of Vector Borne and Neglected Tropical Diseases, Ministry of Health, Nairobi, Kenya
| |
Collapse
|
4
|
Pion SDS, Chesnais CB, Awaca-Uvon NP, Vlaminck J, Abdou A, Kunyu-Shako B, Kuyangisa Simuna G, Tambwe JP, Weil GJ, Boussinesq M. The impact of four years of semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: A community-based study in the Democratic Republic of the Congo. PLoS Negl Trop Dis 2020; 14:e0008322. [PMID: 32574160 PMCID: PMC7337406 DOI: 10.1371/journal.pntd.0008322] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2020] [Revised: 07/06/2020] [Accepted: 04/24/2020] [Indexed: 02/03/2023] Open
Abstract
Background The World Health Organization now recommends semiannual mass drug administration (MDA) of albendazole with integrated vector management as an option for eliminating lymphatic filariasis (LF) in areas of loiasis-endemic countries where it may not be safe to use diethylcarbamazine or ivermectin in MDA programs. However, the published evidence base to support this policy is thin, and uptake by national programs has been slow. Methodology/Principal findings We conducted a community trial to assess the impact of semiannual MDA on lymphatic filariasis and soil-transmitted helminth infections (STH) in two villages in the Bandundu province of the Democratic Republic of the Congo with moderately high prevalences for LF and hookworm infections. MDA with albendazole was provided every six months from June 2014 to December 2017 with treatment coverages of the eligible population (all ≥ 2 year of age) that ranged between 56% and 88%. No adverse effects were reported during the trial. Evaluation at 48 months, (i.e. 6 months after the 8th round of MDA), showed that W. bancrofti microfilaremia (Mf) prevalence in the study communities had decreased between 2014 to 2018 from 12% to 0.9% (p<0.001). The prevalence of W. bancrofti antigenemia was also significantly reduced from 31.6% to 8.5% (p<0.001). MDA with albendazole also reduced hookworm, Ascaris lumbricoides and Trichuris trichiura infection prevalences in the community from 58.6% to 21.2% (p<0.001), from 14.0% to 1.6% and 4.1% to 2.9%, respectively. Hookworm and Ascaris infection intensities were reduced by 93% (p = 0.02) and 57% (p = 0.03), respectively. In contrast, Trichuris infection intensity was not significantly reduced by MDA (p = 0.61) over this time period. Conclusion/Significance These results provide strong evidence that semiannual MDA with albendazole alone is a safe and effective strategy for LF elimination in Central Africa. Community MDA also had a major impact on STH infections. In low-income rural settings of Africa, populations are commonly affected by multiple parasitic diseases. Some of these diseases have been targeted for elimination through dedicated national or international programs. In 2012, the World Health Organization (WHO) defined a specific strategy to eliminate lymphatic filariasis, the disease responsible for elephantiasis, in central Africa. This strategy consists in treating the whole population living in endemic areas every six months with a single donated drug—albendazole. Together with the use of the night bed nets distributed as part of malaria programs, it was expected that this strategy could interrupt the transmission and eliminate lymphatic filariasis locally within period of 4 to 7 years. Here, we evaluated this strategy in two endemic communities near Bandundu in the Democratic Republic of the Congo. We also assessed the impact of the semiannual community treatments on three species of gastrointestinal parasitic worms. Our results suggest that semiannual MDA with albendazole is effective for LF elimination in Central Africa, but they also indicate that drug-based only intervention is not enough to eliminate gastrointestinal worm infections in areas with high transmission.
Collapse
Affiliation(s)
- Sébastien D. S. Pion
- French National Research Institute for Sustainable Development, Montpellier, France
- * E-mail:
| | - Cédric B. Chesnais
- French National Research Institute for Sustainable Development, Montpellier, France
| | | | - Johnny Vlaminck
- Ministry of health, Kinshasa, Democratic Republic of the Congo
- Ghent University, Merelbeke, Belgium
| | - Anlimou Abdou
- French National Research Institute for Sustainable Development, Montpellier, France
| | - Billy Kunyu-Shako
- National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo
| | | | | | - Gary J. Weil
- Washington University School of Medicine, St. Louis, Missouri, United States of America
| | - Michel Boussinesq
- French National Research Institute for Sustainable Development, Montpellier, France
| |
Collapse
|
5
|
Affiliation(s)
| | - Gary J Weil
- Washington University School of Medicine, St. Louis, MO
| | - James W Kazura
- Case Western Reserve University School of Medicine, Cleveland, OH
| |
Collapse
|
6
|
Sahu P, Gupta P, Bhardwaj M, Durga CK. Isolated Epitrochlear Filarial Lymphadenopathy: Cytomorphological Diagnosis of an Unusual Presentation. Turk Patoloji Derg 2020; 36:87-89. [PMID: 29630086 PMCID: PMC10512672 DOI: 10.5146/tjpath.2018.01423] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2018] [Accepted: 02/19/2018] [Indexed: 11/18/2022] Open
Abstract
Filariasis is a major public health problem in tropical countries like India. Despite the large number of people at risk, detection of eggs with or without larva (microfilaria) on fine-needle aspiration cytology is very unusual, especially in an uncommon site or incidentally detected in clinically unsuspected cases of filariasis with the absence of microfilariae in the peripheral blood. A 19-year-old male presented with swelling over medial aspect of left arm (just above the elbow), with no other specific signs and symptoms. Fine needle aspiration cytology revealed an adult gravid female filarial worm in a background of reactive lymphoid cells and lymphohistiocytic clusters. We report a case with elaborate fine needle aspiration cytology findings of filarial worm infestation with unusual presentation of isolated epitrochlear lymph node involvement in a clinically unsuspected case and recommend clinicians and pathologists to consider a high index of suspicion for such infections at uncommon sites especially in endemic territories, as early diagnosis and treatment prevent the more severe manifestations of disease.
Collapse
Affiliation(s)
- Priya Sahu
- Department of Pathology, Post Graduate Institute of Medical Education and Research, Dr. Ram Manohar Lohia Hospital, New Delhi, India
| | - Prajwala Gupta
- Department of Pathology, Post Graduate Institute of Medical Education and Research, Dr. Ram Manohar Lohia Hospital, New Delhi, India
| | - Minakshi Bhardwaj
- Department of Pathology, Post Graduate Institute of Medical Education and Research, Dr. Ram Manohar Lohia Hospital, New Delhi, India
| | - CK Durga
- Department of Post Graduate Institute of Medical Education and Research, Dr. Ram Manohar Lohia Hospital, New Delhi, India
| |
Collapse
|
7
|
Ramzy RMR, Kamal HA, Hassan MA, Haggag AA. Elimination of lymphatic filariasis as a public health problem from the Arab Republic of Egypt. Acta Trop 2019; 199:105121. [PMID: 31400299 DOI: 10.1016/j.actatropica.2019.105121] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2019] [Revised: 07/30/2019] [Accepted: 07/31/2019] [Indexed: 12/23/2022]
Abstract
Lymphatic filariasis (LF) has been known in Egypt since ancient times. By 1930s it was recognized to be a major public health problem in the Nile Delta, and to be caused by Wuchereria bancrofti and transmitted by Culex pipiens. Remarkably, as a result of widespread DEC treatment and intensive vector control by the Ministry of Health and Population (MoHP), the infection rate of LF declined in the 1960s. However, relaxation of these efforts resulted in resurgence of filariasis in the 1980s and 1990s. In 2000, Egypt was among the first countries to join the WHO global efforts to eliminate LF as a public health problem by initiating a national LF elimination programme (NLFEP). This article reviews the history of LF control activities and summarizes the NLFEP extensive interventions to eliminate LF in Egypt. Based on MoHP data, mass drug administration (MDA) with DEC and ALB was started in 2000 in 161 implementation units (IUs). Additional IUs were included in subsequent MDA rounds, with the last IU included in 2007. MDA stopping surveys were conducted based on WHO guidelines (2005; 2011). Information about the presence of those suffering from lymphoedema/elephantiasis and hydrocele patients was collected, and care provided to those needing care in five rural health units (RHU) by primary health care system providers who were given training on LF morbidity management and disability prevention (MMDP). The NLFEP made excellent progress due to strong collaboration between different ministries, through intensive training and supervision, and the use of advocacy for mobilization of endemic communities. The epidemiological coverage for all MDA rounds was effectively ≥80%. Antigenemia levels found in schoolchildren during transmission assessment surveys (TAS) in 166 IUs approximately 10 years after stopping MDA was 0%. In 2017, TAS conducted in additional 29 IUs indicated 0.1% antigenemia and 0% microfilaremia. In 2015, the registration of chronic LF patients was updated to 1472 lymphoedema and 18 hydrocele patients. Lymphoedema patients were trained on self-management, and hydrocele patients were referred to local General Hospitals for surgery. Thus, after over a decade of sustained effort, Egypt met the WHO criteria for successful elimination of LF as a public health problem. In December 2017, WHO validated Egypt as the first country in the Eastern Mediterranean Region to successfully achieve elimination.
Collapse
Affiliation(s)
- Reda M R Ramzy
- National Nutrition Institute, General Organization for Teaching Hospitals and Institutes, Cairo, Egypt.
| | | | | | | |
Collapse
|
8
|
Maroto-Camino C, Hernandez-Pastor P, Awaca N, Safari L, Hemingway J, Massangaie M, Whitson D, Jeffery C, Valadez JJ. Improved assessment of mass drug administration and health district management performance to eliminate lymphatic filariasis. PLoS Negl Trop Dis 2019; 13:e0007337. [PMID: 31276494 PMCID: PMC6636779 DOI: 10.1371/journal.pntd.0007337] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2018] [Revised: 07/17/2019] [Accepted: 03/27/2019] [Indexed: 11/20/2022] Open
Abstract
Lymphatic filariasis (LF) elimination as a public health problem requires the interruption of transmission by administration of preventive mass drug administration (MDA) to the eligible population living in endemic districts. Suboptimal MDA coverage leads to persistent parasite transmission with consequential infection, disease and disability, and the need for continuing MDA rounds, requiring considerable investment. Routine coverage reports must be verified in each MDA implementation unit (IU) due to incorrect denominators and numerators used to calculate coverage estimates with administrative data. IU are usually the health districts. Coverage is verified so IU teams can evaluate their outreach and take appropriate action to improve performance. Mozambique and the Democratic Republic of Congo (DRC) have conducted MDA campaigns for LF since 2009 and 2014, respectively. To verify district reports and assess the declared achievement using administrative data of the minimum 80% coverage of eligible people (or 65% of the total population), both countries conducted rapid probability surveys using Lot Quality Assurance Sampling (LQAS)(n = 1102) in 2015 and 2016 in 58 IU in 49 districts. The surveys identified IU with suboptimal coverage, reasons residents did not take the medication, place where the medication was received, information sources, and knowledge about diseases prevented by the MDA. LQAS identified four inadequately covered IU triggering district team performance reviews with provincial and national teams and district retreatment. Provincial estimates using probability samples (weighted by populations sizes) were 10 and 17 percentage points lower than reported coverage in DRC and Mozambique. The surveys identified: absence from home during annual MDA rounds as the main reason for low performance and provided valuable information about pre-campaign and campaign activities resulting in improved strategies and continued progress towards elimination of LF and co-endemic Neglected Tropical Diseases. Global elimination of lymphatic filariasis (LF) is achieved through treatment of at-risk populations with annual or bi-annual mass drug administration campaigns. In Africa campaigns need to be completed in 32 countries with 343 million people at risk. The World Health Organisation recommends verification of the campaign’s administrative records using household cluster surveys at least once every 5-years. However, cluster surveys are expensive and usually completed in a few districts only or at sub-national levels. Together with National Programmes in Mozambique and the Democratic Republic of the Congo (DRC) we adapted Lot Quality Assurance Sampling (LQAS) methods to verify campaign coverage because it is relatively inexpensive in comparison to other survey approaches, provides information and facilitates actions at the Implementation Unit (IU) level, which is usually the district. LQAS signals IU whose performance is likely to need improvement because MDA coverage is below the coverage target. Our results show consistently that administrative records over-estimated campaign coverage and did not detect implementation and coverage problems due to errors in numerators and denominators, incorrect reporting, and/or incorrect aggregation of tally sheets. The LQAS verification approach prompted immediate action to remedy coverage shortfalls averting persistent LF transmission and disease, and the costs associated with failed campaigns. Our study demonstrates that a rapid probability sample to verify coverage provides district teams with information after each campaign which can be used for action, and that one coverage survey every 5-years is insufficient for infectious disease elimination in highly endemic settings where achievement of optimal coverage is essential. It also demonstrates that LQAS provides a decentralised assessment, sensitive for detecting and ameliorating programme bottlenecks and can be used to verify MDA in other countries.
Collapse
Affiliation(s)
- Carmen Maroto-Camino
- Department of International Health, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - Pilar Hernandez-Pastor
- Department of International Health, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - Naomi Awaca
- National NTD Programme, Democratic Republic of Congo, Ministère de la Sante Publique, Gombe, Kinshasa
| | - Lebon Safari
- Department of International Health, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - Janet Hemingway
- Department of International Health, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - Marilia Massangaie
- National NTD Programme, Direção Nacional da Saúde Publica, Ministério da Saúde, Eduardo Modliane, Maputo, Mozambique
| | - Donald Whitson
- Department of International Health, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - Caroline Jeffery
- Department of International Health, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - Joseph J. Valadez
- Department of International Health, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
- * E-mail:
| |
Collapse
|
9
|
Edi C, Bjerum CM, Ouattara AF, Chhonker YS, Penali LK, Méité A, Koudou BG, Weil GJ, King CL, Murry DJ. Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire. PLoS Negl Trop Dis 2019; 13:e0007325. [PMID: 31107869 PMCID: PMC6550417 DOI: 10.1371/journal.pntd.0007325] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2018] [Revised: 06/05/2019] [Accepted: 03/23/2019] [Indexed: 11/25/2022] Open
Abstract
Background A single co-administered dose of ivermectin (IVM) plus diethylcarbamazine (DEC) plus albendazole (ALB), or triple-drug therapy, was recently found to be more effective for clearing microfilariae (Mf) than standard DEC plus ALB currently used for mass drug administration programs for lymphatic filariasis (LF) outside of sub-Saharan Africa. Triple-drug therapy has not been previously tested in LF-uninfected individuals from Africa. This study evaluated the pharmacokinetics (PK), safety, and efficacy of triple-drug therapy in people with and without Wuchereria bancrofti infection in West Africa. Methods In this open-label cohort study, treatment-naïve microfilaremic (>50 mf/mL, n = 32) and uninfected (circulating filarial antigen negative, n = 24) adults residing in Agboville district, Côte d’Ivoire, were treated with a single dose of IVM plus DEC plus ALB, and evaluated for adverse events (AEs) until 7 days post treatment. Drug levels were assessed by liquid chromatography and mass spectrometry. Persons responsible for assessing AEs were blinded to participants’ infection status. Findings There was no difference in AUC0-inf or Cmax between LF-infected and uninfected participants (P>0.05 for all comparisons). All subjects experienced mild AEs; 28% and 25% of infected and uninfected participants experienced grade 2 AEs, respectively. There were no severe or serious adverse events. Only fever (16 of 32 versus 4 of 24, P<0.001) and scrotal pain/swelling in males (6 of 20 versus 0 of 12, P = 0.025) were more frequent in infected than uninfected participants. All LF positive participants were amicrofilaremic at 7 days post-treatment and 27 of 31 (87%) remained amicrofilaremic 12 months after treatment. Conclusions Moderate to heavy W. bancrofti infection did not affect PK parameters for IVM, DEC or ALB following a single co-administered dose of these drugs compared to uninfected individuals. The drugs were well tolerated. This study confirmed the efficacy of the triple-drug therapy for clearing W. bancrofti Mf and has added important information to support the use of this regimen in LF elimination programs in areas of Africa without co-endemic onchocerciasis or loiasis. Trial registration ClinicalTrials.gov NCT02845713. Lymphatic filariasis is a mosquito-borne infection that causes disability in the form of lymphedema, hydroceles, and elephantiasis. It has been targeted for global elimination based on mass drug administration in the total population at risk including many people uninfected with LF. Recently, a single co-administered dose of IVM + DEC + ALB has been shown to be much more effective than the standard treatment with DEC + ALB for sustained clearance of Mf for 3 years based on studies in Papua New Guinea. This study confirms the efficacy and safety of triple-drug therapy for clearing of Wuchereria bancrofti Mf in an African population. The presence of LF did not affect drug levels and the medicines were well tolerated, with 28% and 25% rate of moderate AEs in infected and uninfected individuals respectively, and no severe or serious AEs, supporting the use of triple-drug therapy for mass drug administration. This study shows for the first time that triple-drug therapy also has a potent macrofilaricidal effect, as determined by the reduction in circulating filarial antigen and inactivation of worm nests one year following treatment.
Collapse
Affiliation(s)
- Constant Edi
- Centre Suisse de Recherche Scientifique en Côte d’Ivoire, Côte d’Ivoire
| | - Catherine M. Bjerum
- Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Allassane F. Ouattara
- Centre Suisse de Recherche Scientifique en Côte d’Ivoire, Côte d’Ivoire
- Université Nangui Abrogoua, Côte d’Ivoire
| | - Yashpal S. Chhonker
- Dept of Pharmacy Practice, University of Nebraska Medical Center, Omaha, NE, United States of America
| | | | - Aboulaye Méité
- Programme National de la Lutte Contre la Schistosomiase, les Geohelminthiases et la Filariose Lymphatique, Abidjan, Côte d’Ivoire
| | - Benjamin G. Koudou
- Centre Suisse de Recherche Scientifique en Côte d’Ivoire, Côte d’Ivoire
- Université Nangui Abrogoua, Côte d’Ivoire
- Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, United Kingdom
| | - Gary J. Weil
- Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America
| | - Christopher L. King
- Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
- Veterans Affairs Research Service, Cleveland Veterans Affairs Medical Center, United States of America
- * E-mail:
| | - Daryl J. Murry
- Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, United States of America
| |
Collapse
|
10
|
Nchoutpouen E, Talipouo A, Djiappi-Tchamen B, Djamouko-Djonkam L, Kopya E, Ngadjeu CS, Doumbe-Belisse P, Awono-Ambene P, Kekeunou S, Wondji CS, Antonio-Nkondjio C. Culex species diversity, susceptibility to insecticides and role as potential vector of Lymphatic filariasis in the city of Yaoundé, Cameroon. PLoS Negl Trop Dis 2019; 13:e0007229. [PMID: 30943198 PMCID: PMC6464241 DOI: 10.1371/journal.pntd.0007229] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2018] [Revised: 04/15/2019] [Accepted: 02/10/2019] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Culex species are widespread across Cameroon and responsible for high burden of nuisance in most urban settings. However, despite their high nuisance, they remain less studied compared to anophelines. The present study aimed to assess Culex species distribution, susceptibility to insecticide, bionomics and role in Lymphatic Filariasis (LF) transmission in the city of Yaoundé. METHODS Mosquito collections were conducted from March to December 2017 using Centre for Disease Control light traps (CDC-LT), human landing catches (HLC) and larval collections. Mosquitoes were identified using morphological identification keys. Mosquitoes from the Culex pipiens complex were further identified using Polymerase Chain Reaction (PCR) to assess the presence of sibling species. Bioassays were conducted with 2-5 day-old unfed females to assess mosquito susceptibility to DDT, permethrin, deltamethrin and bendiocarb following WHO guidelines. Dead, control and surviving mosquitoes from bioassays were screened by PCR to detect the presence of knockdown resistance (kdr) alleles. Pools of mosquitoes were examined by PCR to detect the presence of Wuchereria bancrofti. RESULTS A total of 197,956 mosquitoes belonging to thirteen species were collected. The density of mosquito collected varied according to the collection methods, districts and seasons. Culex quinquefasciatus emerged as the most abundant and the only species of the Culex pipiens complex in Yaoundé. Culex species were found breeding in different types of breeding sites including polluted and unpolluted sites. All Culex species including Cx antennatus, Cx duttoni, Cx perfuscus and Cx tigripes were found to be highly resistant to permethrin, deltamethrin and DDT. Culex quinquefasciatus was also found to be resistant to bendiocarb. A high frequency of the West Africa kdr allele was recorded in resistant Cx. quinquefasciatus. Out of the 247 pooled samples of 25 Culex spp. examined for the presence of Wuchereria bancrofti, none was found infected. CONCLUSION The study confirms the high adaptation of Culex species particularly Culex quinquefasciatus to the urban environment and no implication of this species in the transmission of LF in Yaoundé Cameroon. Culex species predominance in urban settings highlight potential transmission risk of West Nile and rift valley fever in Yaoundé.
Collapse
Affiliation(s)
- Elysee Nchoutpouen
- Laboratoire de Recherche sur le Paludisme, Organisation de Coordination pour la lutte Contreles Endémies en Afrique Centrale (OCEAC), Yaoundé, Cameroon
- Faculty of Science, University of Yaoundé I, Yaoundé, Cameroon
| | - Abdou Talipouo
- Laboratoire de Recherche sur le Paludisme, Organisation de Coordination pour la lutte Contreles Endémies en Afrique Centrale (OCEAC), Yaoundé, Cameroon
- Faculty of Science, University of Yaoundé I, Yaoundé, Cameroon
| | - Borel Djiappi-Tchamen
- Laboratoire de Recherche sur le Paludisme, Organisation de Coordination pour la lutte Contreles Endémies en Afrique Centrale (OCEAC), Yaoundé, Cameroon
- Vector Borne Infectious Disease Unit of the Laboratory of Applied Biology and Ecology (VBID-LABEA), Department of Animal Biology, Faculty of Science, University of Dschang, Dschang, Cameroon
| | - Landre Djamouko-Djonkam
- Laboratoire de Recherche sur le Paludisme, Organisation de Coordination pour la lutte Contreles Endémies en Afrique Centrale (OCEAC), Yaoundé, Cameroon
- Vector Borne Infectious Disease Unit of the Laboratory of Applied Biology and Ecology (VBID-LABEA), Department of Animal Biology, Faculty of Science, University of Dschang, Dschang, Cameroon
| | - Edmond Kopya
- Laboratoire de Recherche sur le Paludisme, Organisation de Coordination pour la lutte Contreles Endémies en Afrique Centrale (OCEAC), Yaoundé, Cameroon
- Faculty of Science, University of Yaoundé I, Yaoundé, Cameroon
| | - Carmene Sandra Ngadjeu
- Laboratoire de Recherche sur le Paludisme, Organisation de Coordination pour la lutte Contreles Endémies en Afrique Centrale (OCEAC), Yaoundé, Cameroon
- Faculty of Science, University of Yaoundé I, Yaoundé, Cameroon
| | - Patricia Doumbe-Belisse
- Laboratoire de Recherche sur le Paludisme, Organisation de Coordination pour la lutte Contreles Endémies en Afrique Centrale (OCEAC), Yaoundé, Cameroon
- Faculty of Science, University of Yaoundé I, Yaoundé, Cameroon
| | - Parfait Awono-Ambene
- Laboratoire de Recherche sur le Paludisme, Organisation de Coordination pour la lutte Contreles Endémies en Afrique Centrale (OCEAC), Yaoundé, Cameroon
| | | | - Charles Sinclair Wondji
- Vector Biology Liverpool School of Tropical medicine Pembroke Place, Liverpool, United Kingdom
| | - Christophe Antonio-Nkondjio
- Laboratoire de Recherche sur le Paludisme, Organisation de Coordination pour la lutte Contreles Endémies en Afrique Centrale (OCEAC), Yaoundé, Cameroon
- Vector Biology Liverpool School of Tropical medicine Pembroke Place, Liverpool, United Kingdom
| |
Collapse
|
11
|
Jacobs RT, Lunde CS, Freund YR, Hernandez V, Li X, Xia Y, Carter DS, Berry PW, Halladay J, Rock F, Stefanakis R, Easom E, Plattner JJ, Ford L, Johnston KL, Cook DAN, Clare R, Cassidy A, Myhill L, Tyrer H, Gamble J, Guimaraes AF, Steven A, Lenz F, Ehrens A, Frohberger SJ, Koschel M, Hoerauf A, Hübner MP, McNamara CW, Bakowski MA, Turner JD, Taylor MJ, Ward SA. Boron-Pleuromutilins as Anti- Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis. J Med Chem 2019; 62:2521-2540. [PMID: 30730745 PMCID: PMC6421521 DOI: 10.1021/acs.jmedchem.8b01854] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2018] [Indexed: 01/07/2023]
Abstract
A series of pleuromutilins modified by introduction of a boron-containing heterocycle on C(14) of the polycyclic core are described. These analogs were found to be potent anti- Wolbachia antibiotics and, as such, may be useful in the treatment of filarial infections caused by Onchocerca volvulus, resulting in Onchocerciasis or river blindness, or Wuchereria bancrofti and Brugia malayi and related parasitic nematodes resulting in lymphatic filariasis. These two important neglected tropical diseases disproportionately impact patients in the developing world. The lead preclinical candidate compound containing 7-fluoro-6-oxybenzoxaborole (15, AN11251) was shown to have good in vitro anti- Wolbachia activity and physicochemical and pharmacokinetic properties providing high exposure in plasma. The lead was effective in reducing the Wolbachia load in filarial worms following oral administration to mice.
Collapse
Affiliation(s)
- Robert T. Jacobs
- Anacor
Pharmaceuticals, 1020
East Meadow Circle, Palo Alto, California 94303, United States
| | - Christopher S. Lunde
- Anacor
Pharmaceuticals, 1020
East Meadow Circle, Palo Alto, California 94303, United States
| | - Yvonne R. Freund
- Anacor
Pharmaceuticals, 1020
East Meadow Circle, Palo Alto, California 94303, United States
| | - Vincent Hernandez
- Anacor
Pharmaceuticals, 1020
East Meadow Circle, Palo Alto, California 94303, United States
| | - Xianfeng Li
- Anacor
Pharmaceuticals, 1020
East Meadow Circle, Palo Alto, California 94303, United States
| | - Yi Xia
- Anacor
Pharmaceuticals, 1020
East Meadow Circle, Palo Alto, California 94303, United States
| | - David S. Carter
- Anacor
Pharmaceuticals, 1020
East Meadow Circle, Palo Alto, California 94303, United States
| | - Pamela W. Berry
- Anacor
Pharmaceuticals, 1020
East Meadow Circle, Palo Alto, California 94303, United States
| | - Jason Halladay
- Anacor
Pharmaceuticals, 1020
East Meadow Circle, Palo Alto, California 94303, United States
| | - Fernando Rock
- Anacor
Pharmaceuticals, 1020
East Meadow Circle, Palo Alto, California 94303, United States
| | - Rianna Stefanakis
- Anacor
Pharmaceuticals, 1020
East Meadow Circle, Palo Alto, California 94303, United States
| | - Eric Easom
- Anacor
Pharmaceuticals, 1020
East Meadow Circle, Palo Alto, California 94303, United States
| | - Jacob J. Plattner
- Anacor
Pharmaceuticals, 1020
East Meadow Circle, Palo Alto, California 94303, United States
| | - Louise Ford
- Centre
for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K.
| | - Kelly L. Johnston
- Centre
for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K.
| | - Darren A. N. Cook
- Centre
for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K.
| | - Rachel Clare
- Centre
for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K.
| | - Andrew Cassidy
- Centre
for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K.
| | - Laura Myhill
- Centre
for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K.
| | - Hayley Tyrer
- Centre
for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K.
| | - Joanne Gamble
- Centre
for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K.
| | - Ana F. Guimaraes
- Centre
for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K.
| | - Andrew Steven
- Centre
for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K.
| | - Franziska Lenz
- Institute
for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Sigmund Freud Str. 25, 53127 Bonn, Germany
| | - Alexandra Ehrens
- Institute
for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Sigmund Freud Str. 25, 53127 Bonn, Germany
| | - Stefan J. Frohberger
- Institute
for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Sigmund Freud Str. 25, 53127 Bonn, Germany
| | - Marianne Koschel
- Institute
for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Sigmund Freud Str. 25, 53127 Bonn, Germany
| | - Achim Hoerauf
- Institute
for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Sigmund Freud Str. 25, 53127 Bonn, Germany
| | - Marc P. Hübner
- Institute
for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Sigmund Freud Str. 25, 53127 Bonn, Germany
| | - Case W. McNamara
- Calibr, 11119 North
Torrey Pines Road, Suite 100, La Jolla, California 92037, United States
| | - Malina A. Bakowski
- Calibr, 11119 North
Torrey Pines Road, Suite 100, La Jolla, California 92037, United States
| | - Joseph D. Turner
- Centre
for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K.
| | - Mark J. Taylor
- Centre
for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K.
| | - Stephen A. Ward
- Centre
for Drugs and Diagnostics, Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, U.K.
| |
Collapse
|
12
|
Minetti C, Tettevi EJ, Mechan F, Prada JM, Idun B, Biritwum NK, Osei-Atweneboana MY, Reimer LJ. Elimination within reach: A cross-sectional study highlighting the factors that contribute to persistent lymphatic filariasis in eight communities in rural Ghana. PLoS Negl Trop Dis 2019; 13:e0006994. [PMID: 30608931 PMCID: PMC6342320 DOI: 10.1371/journal.pntd.0006994] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2018] [Revised: 01/22/2019] [Accepted: 11/13/2018] [Indexed: 12/20/2022] Open
Abstract
Background Despite the progress achieved in scaling-up mass drug administration (MDA) for lymphatic filariasis (LF) in Ghana, communities with persistent LF still exist even after 10 years of community treatment. To understand the reasons for persistence, we conducted a study to assess the status of disease elimination and understand the adherence to interventions including MDA and insecticide treated nets. Methodology and principal findings We conducted a parasitological and epidemiological cross-sectional study in adults from eight villages still under MDA in the Northern Region savannah and the coastal Western Region of the country. Prevalence of filarial antigen ranged 0 to 32.4% and in five villages the prevalence of night blood microfilaria (mf) was above 1%, ranging from 0 to 5.7%. Median mf density was 67 mf/ml (range: 10–3,560). LF antigen positivity was positively associated with male sex but negatively associated with participating in MDA the previous year. Male sex was also associated with a decreased probability of participating in MDA. A stochastic model (TRANSFIL) was used to assess the expected microfilaria prevalence under different MDA coverage scenarios using historical data on one community in the Western Region. In this example, the model simulations suggested that the slow decline in mf prevalence is what we would expect given high baseline prevalence and a high correlation between MDA adherence from year to year, despite high MDA coverage. Conclusions There is a need for an integrated quantitative and qualitative research approach to identify the variations in prevalence, associated risk factors and intervention coverage and use levels between and within regions and districts. Such knowledge will help target resources and enhance surveillance to the communities most at risk and to reach the 2020 LF elimination goals in Ghana. Lymphatic filariasis (LF) is a mosquito-borne disease and a leading cause of disability and chronic morbidity worldwide. Despite the progress achieved so far in stopping LF transmission by treating the affected communities with specific drugs over several years, areas where lymphatic filariasis persists still exist. Understanding the reasons behind this is pivotal to both reach and sustain elimination. We investigated the factors associated with filariasis persistence in various communities still under drug treatment from two regions of Ghana. We reported high variability in disease burden, adherence to drug treatment and mosquito net use between regions and communities. LF infection was associated with men and not taking the drugs, and men were also less likely to take treatment. Using mathematical modelling, we showed that slight increases in treatment coverage will accelerate elimination. Our findings highlight the reasons for LF persistence and provide guidance on how to successfully achieve elimination by refining drug treatment distribution and mosquito control interventions more tailored to individuals and communities. We also demonstrated the value of using field-collected data in mathematical models to assess the current status of disease elimination and to identify the gaps in control interventions.
Collapse
Affiliation(s)
- Corrado Minetti
- Department of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - Edward J. Tettevi
- Department of Environmental Biology and Health, Council for Scientific and Industrial Research Water Research Institute, Accra, Ghana
| | - Frank Mechan
- Department of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - Joaquín M. Prada
- Mathematics Institute, University of Warwick, Coventry, United Kingdom
- School of Veterinary Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom
| | - Bright Idun
- Department of Environmental Biology and Health, Council for Scientific and Industrial Research Water Research Institute, Accra, Ghana
| | | | - Mike Yaw Osei-Atweneboana
- Department of Environmental Biology and Health, Council for Scientific and Industrial Research Water Research Institute, Accra, Ghana
| | - Lisa J. Reimer
- Department of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
- * E-mail:
| |
Collapse
|
13
|
Abstract
Benzimidazole anthelmintics have long been employed for the control of soil-transmitted helminth infections. Flubendazole (FBZ) was approved in 1980 for the treatment of gastrointestinal nematode infections in both veterinary and human medicine. It has also long been known that parenteral administration of FBZ can lead to high macrofilaricidal efficacy in a variety of preclinical models and in humans. As part of an effort to stimulate the discovery and development of new macrofilaricides, particularly for onchocerciasis, research has recently been devoted to the development of new formulations that would afford high oral bioavailability of FBZ, paving the way for potential clinical development of this repurposed drug for the treatment of human filariases. This review summarizes the background information that led to this program and summarizes some of the lessons learned from it.
Collapse
Affiliation(s)
- Timothy G. Geary
- Institute of Parasitology, McGill University, Ste-Anne-de-Bellevue, Québec, Canada
| | - Charles D. Mackenzie
- NTDSC/MDP, Task Force for Global Health, Decatur, Georgia, United States of America
| | - Steven A. Silber
- Johnson & Johnson Global Public Health, Janssen Research and Development, LLC., New Brunswick, New Jersey, United States of America
| |
Collapse
|
14
|
Rajaiah Prabhu P, Moorthy SD, Madhumathi J, Pradhan SN, Perbandt M, Betzel C, Kaliraj P. Wucherria bancrofti glutathione S-Transferase: Insights into the 2.3 Å resolution X-ray structure and function, a therapeutic target for human lymphatic filariasis. Biochem Biophys Res Commun 2018; 505:979-984. [PMID: 30297111 DOI: 10.1016/j.bbrc.2018.09.077] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2018] [Accepted: 09/12/2018] [Indexed: 11/19/2022]
Abstract
The notoriety of parasitic nematode survival is directly related to chronic pathogenicity, which is evident in human lymphatic filariasis. It is a disease of poverty which causes severe disability affecting more than 120 million people worldwide. These nematodes down-regulate host immune system through a myriad of strategies that includes secretion of antioxidant and detoxification enzymes like glutathione-S-transferases (GSTs). Earlier studies have shown Wuchereria bancrofti GST to be a potential therapeutic target. Parasite GSTs catalyse the conjugation of glutathione to xenobiotic and other endogenous electrophiles and are essential for their long-term survival in lymph tissues. Hence, the crystal structure of WbGST along with its cofactor GSH at 2.3 Å resolution was determined. Structural comparisons against host GST reveal distinct differences in the substrate binding sites. The parasite xenobiotic binding site is more substrate/solvent accessible. The structure also suggests the presence of putative non-catalytic binding sites that may permit sequestration of endogenous and exogenous ligands. The structure of WbGST also provides a case for the role of the π-cation interaction in stabilizing catalytic Tyr compared to stabilization interactions described for other GSTs. Hence, the obtained information regarding crucial differences in the active sites will support future design of parasite specific inhibitors. Further, the study also evaluates the inhibition of WbGST and its variants by antifilarial diethylcarbamazine through kinetic assays.
Collapse
Affiliation(s)
| | | | | | | | - Markus Perbandt
- Institute of Biochemistry and Molecular Biology, Hamburg University, Hamburg, Germany
| | - Christian Betzel
- Institute of Biochemistry and Molecular Biology, Hamburg University, Hamburg, Germany.
| | | |
Collapse
|
15
|
Dickson BFR, Graves PM, Aye NN, Nwe TW, Wai T, Win SS, Shwe M, Douglass J, Bradbury RS, McBride WJ. The prevalence of lymphatic filariasis infection and disease following six rounds of mass drug administration in Mandalay Region, Myanmar. PLoS Negl Trop Dis 2018; 12:e0006944. [PMID: 30419025 PMCID: PMC6258426 DOI: 10.1371/journal.pntd.0006944] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2018] [Revised: 11/26/2018] [Accepted: 10/24/2018] [Indexed: 11/19/2022] Open
Abstract
Lymphatic filariasis is widely endemic in Myanmar. Despite the establishment of an elimination program in 2000, knowledge of the remaining burden of disease relies predominantly on programmatic information. To assist the program, we conducted an independent cross-sectional household cluster survey to determine the prevalence of filariasis infection, morbidity and mass-drug administration coverage in four townships of the Mandalay Region: Amarapura, Patheingyi, Tada-U and Wundwin. The survey included 1014 individuals from 430 randomly selected households in 24 villages. Household members one year and older were assessed for antigenaemia using immunochromatographic test cards and if positive, microfilaraemia by night-time thick blood smear. Participants 15 years and older were assessed for filariasis morbidity by ultrasound-assisted clinical examination. The overall prevalence of infection was 2.63% by antigenaemia (95% confidence interval (CI) 1.71-4.04%) and 1.03% by microfilaraemia (95%CI 0.59-1.47%). The prevalence of hydrocoele in adult males was 2.78% (95%CI 1.23-6.15%) and of lymphoedema in both genders was 0% (95%CI 0-0.45%). These results indicate the persistence of filarial infection and transmission despite six rounds of annual mass drug administration and highlight the need for further rounds as well as the implementation of morbidity management programs in the country.
Collapse
Affiliation(s)
- Benjamin F. R. Dickson
- College of Medicine & Dentistry, Division of Tropical Health and Medicine, James Cook University, Cairns, Queensland, Australia
| | - Patricia M. Graves
- College of Public Health, Medical and Veterinary Sciences, Division of Tropical Health and Medicine, James Cook University, Cairns, Queensland, Australia
- James Cook University and World Health Organization Collaborating Centre for the Control of Lymphatic Filariasis, Soil Transmitted Helminths and Other Neglected Tropical Diseases, Cairns, Queensland, Australia
| | - Ni Ni Aye
- Vector Borne Disease Control Unit, Ministry of Health and Sport, Naypyitaw, Myanmar
| | - Thet Wai Nwe
- Vector Borne Disease Control Unit, Ministry of Health and Sport, Naypyitaw, Myanmar
| | - Tint Wai
- Regional Vector Borne Disease Control Unit, Ministry of Health and Sport, Mandalay, Myanmar
| | | | | | - Janet Douglass
- College of Public Health, Medical and Veterinary Sciences, Division of Tropical Health and Medicine, James Cook University, Cairns, Queensland, Australia
- Center for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - Richard S. Bradbury
- School of Health, Medical and Applied Sciences, Central Queensland University, North Rockhampton, Queensland, Australia
| | - William J. McBride
- College of Medicine & Dentistry, Division of Tropical Health and Medicine, James Cook University, Cairns, Queensland, Australia
| |
Collapse
|
16
|
Saeed M, Imran M, Baig MH, Kausar MA, Shahid S, Ahmad I. Virtual screening of natural anti-filarial compounds against glutathione-S-transferase of Brugia malayi and Wuchereria bancrofti. Cell Mol Biol (Noisy-le-grand) 2018; 64:69-73. [PMID: 30403598] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2018] [Revised: 09/25/2018] [Accepted: 10/03/2018] [Indexed: 06/08/2023]
Abstract
Glutathione-S-transferase also referred as GST is one of the major detoxification enzymes in parasitic helminths. The crucial role played by GST in various chronic infections has been well reported. The dependence of nematodes on detoxification enzymes to maintain their survival within the host established the crucial role of GST in filariasis and other related diseases. Hence, this well-established role of GST in filariasis along with its greater nonhomology with its human counterpart makes it an important therapeutic drug target. Here in this study, we have tried to explore the inhibitory potential of some of the well-reported natural ant-filarial compounds against the GST from Wuchereria bancrofti (W.bancrofti) and Brugia malayi (B.malayi). In silico virtual screening, approach was used to screen the selected natural compounds against GST from W.bancrofti and B.malayi. On the basis of our results, here we are reporting some of the natural compounds which were found to be very effective against GSTs. Along with we have also revealed the characteristic of the active site of BmGST and WbGST and the role of important active site residues involve in the binding of natural compounds within the active site of GSTs. This information will oped doors for using natural compounds as anti-filarial therapy and will also be helpful for future drug discovery.
Collapse
Affiliation(s)
- Mohd Saeed
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hail, KSA
| | - Mohd Imran
- Department of Biophysics, All India Institute of Medical Sciences, Ansari nagar, New Delhi, 110029, India
| | - Mohd Hassan Baig
- Department of Medical Biotechnology, Yeungnam University, The Republic of Korea
| | - Mohd Adnan Kausar
- Department of Biochemistry, college of Medicine, University of Hail, KSA
| | - Sma Shahid
- Department of Biochemistry, college of Medicine, University of Hail, KSA
| | - Irfan Ahmad
- Department of Clinical Laboratory Science, College of Applied Medical Sciences, King Khalid University. Abha, KSA
| |
Collapse
|
17
|
Martin D, Wiegand R, Goodhew B, Lammie P, Mkocha H, Kasubi M. Impact of Ivermectin Mass Drug Administration for Lymphatic Filariasis on Scabies in Eight Villages in Kongwa District, Tanzania. Am J Trop Med Hyg 2018; 99:937-939. [PMID: 30062986 PMCID: PMC6159570 DOI: 10.4269/ajtmh.18-0018] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2018] [Accepted: 05/20/2018] [Indexed: 11/29/2022] Open
Abstract
Scabies was recently added to the World Health Organization list of neglected tropical diseases. The ability to treat scabies with oral ivermectin makes a mass drug administration (MDA) campaign a feasible option for scabies control. Ivermectin MDA in communities endemic for lymphatic filariasis (LF) or onchocerciasis may already be having an impact on scabies. We examined the effect of ivermectin MDA for LF on scabies prevalence over 4 years in eight Tanzanian villages. At baseline, 4.4% (95% confidence interval [CI]: 3.7-5.4) of individuals tested positive for scabies, decreasing to 0.84% (95% CI: 0.51-1.4) after one round of ivermectin MDA but increased in Year 3 (2.5% [95% CI: 1.9-3.3]) and Year 4 (2.9% [95% CI: 2.2-3.8]). Most scabies cases were seen in children younger than 15 years. The data suggest that single-dose ivermectin MDA may not be effective in attaining long-term decreases when scabies prevalence is less than 5%.
Collapse
Affiliation(s)
- Diana Martin
- Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Ryan Wiegand
- Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Brook Goodhew
- Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Patrick Lammie
- Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | | |
Collapse
|
18
|
Sheel M, Sheridan S, Gass K, Won K, Fuimaono S, Kirk M, Gonzales A, Hedtke SM, Graves PM, Lau CL. Identifying residual transmission of lymphatic filariasis after mass drug administration: Comparing school-based versus community-based surveillance - American Samoa, 2016. PLoS Negl Trop Dis 2018; 12:e0006583. [PMID: 30011276 PMCID: PMC6062125 DOI: 10.1371/journal.pntd.0006583] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Revised: 07/26/2018] [Accepted: 06/05/2018] [Indexed: 11/18/2022] Open
Abstract
INTRODUCTION Under the Global Programme to Eliminate Lymphatic Filariasis (LF), American Samoa conducted seven rounds of mass drug administration (MDA) from 2000-2006. The World Health Organization recommends systematic post-MDA surveillance using Transmission Assessment Surveys (TAS) for epidemiological assessment of recent LF transmission. We compared the effectiveness of two survey designs for post-MDA surveillance: a school-based survey of children aged 6-7 years, and a community-based survey targeting people aged ≥8 years. METHODS In 2016, we conducted a systematic school-based TAS in all elementary schools (N = 29) and a cluster survey in 28 villages on the two main islands of American Samoa. We collected information on demographics and risk factors for infection using electronic questionnaires, and recorded geo-locations of schools and households. Blood samples were collected to test for circulating filarial antigen (CFA) using the Alere Filariasis Test Strip. For those who tested positive, we prepared slides for microscopic examination of microfilaria and provided treatment. Descriptive statistics were performed for questionnaire variables. Data were weighted and adjusted to account for sampling design and sex for both surveys, and for age in the community survey. RESULTS The school-based TAS (n = 1143) identified nine antigen-positive children and found an overall adjusted CFA prevalence of 0.7% (95% CI: 0.3-1.8). Of the nine positive children, we identified one microfilariaemic 7-year-old child. The community-based survey (n = 2507, 711 households) identified 102 antigen-positive people, and estimated an overall adjusted CFA prevalence of 6.2% (95% CI: 4.5-8.6). Adjusted village-level prevalence ranged from 0-47.1%. CFA prevalence increased with age and was higher in males. Of 86 antigen-positive community members from whom slides were prepared, 22 (25.6%) were microfilaraemic. School-based TAS had limited sensitivity (range 0-23.8%) and negative predictive value (range 25-83.3%) but had high specificity (range 83.3-100%) and positive predictive value (range 0-100%) for identifying villages with ongoing transmission. CONCLUSIONS American Samoa failed the school-based TAS in 2016, and the community-based survey identified higher than expected numbers of antigen-positive people. School-based TAS was logistically simpler and enabled sampling of a larger proportion of the target population, but the results did not provide a good indication of the overall CFA prevalence in older age groups and was not sensitive at identifying foci of ongoing transmission. The community-based survey, although operationally more challenging, identified antigen-positive individuals of all ages, and foci of high antigen prevalence. Both surveys confirmed recrudescence of LF transmission.
Collapse
Affiliation(s)
- Meru Sheel
- National Centre for Epidemiology and Population Health, Australian National University, Acton, Australian Capital Territory, Australia
- National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia
- * E-mail:
| | - Sarah Sheridan
- Department of Global Health, Research School of Population Health, Australian National University, Acton, Australian Capital Territory, Australia
| | - Katherine Gass
- Neglected Tropical Disease Support Center, The Task Force for Global Health, Decatur, Georgia, United States of America
| | - Kimberly Won
- Centers for Disease Control and Prevention, Division of Parasitic Diseases and Malaria, Atlanta, Georgia, United States of America
| | | | - Martyn Kirk
- National Centre for Epidemiology and Population Health, Australian National University, Acton, Australian Capital Territory, Australia
| | - Amor Gonzales
- Lyndon B Johnson Tropical Medical Center, Pago Pago, American Samoa
| | - Shannon M. Hedtke
- Department of Animal, Plant and Soil Sciences, La Trobe University, Bundoora, Victoria, Australia
| | - Patricia M. Graves
- College of Public Health, Medical and Veterinary Sciences, James Cook University, Cairns, Queensland, Australia
| | - Colleen L. Lau
- Department of Global Health, Research School of Population Health, Australian National University, Acton, Australian Capital Territory, Australia
| |
Collapse
|
19
|
da Silva JSF, Braga C, Duarte FM, Oliveira P, Feitosa Luna C, Marcondes M, Araújo J, Grilis MR, de Souza Melo PFA, Brandão E, Rocha A. Effectiveness of annual single doses of diethylcarbamazine citrate among bancroftian filariasis infected individuals in an endemic area under mass drug administration in Brazil. Pathog Glob Health 2018; 112:274-280. [PMID: 30111259 PMCID: PMC6225505 DOI: 10.1080/20477724.2018.1498821] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Abstract
The Global Program to Eliminate Lymphatic Filariasis has achieved extraordinary success in reducing transmission and preventing morbidity through mass drug administration (MDA) to the population at-risk. Brazil is the only currently using diethylcarbamazine citrate (DEC) alone for MDA, so an assessment of its effectiveness is needed. We report the trends of filarial markers in a cohort of 175 individuals infected with Wuchereria bancrofti in areas that underwent MDA in the city of Olinda, Northeastern Brazil. The prospective study was conducted between 2007 and 2012 (corresponding to five annual MDA rounds). The quantification of microfilaraemia (QMFF) was assessed by filtration. Circulating filarial antigen (CFA) was detected through immunochromatographic point-of-care test (POCT-ICT) and Og4C3-ELISA whereas antifilarial antibody titres (IgG4) were assessed through Bm14 assay. The CFA and IgG4 titres were measured by Optical Density (OD). The main characteristics at baseline, MDA coverage and the trend of filarial infection markers during follow up were described. The trend of filarial markers in relation to time (years of MDA), sex and age were analysed through Generalized Estimating Equations (GEE) models. The models demonstrated a significant decrease in all markers during MDA. The probability of remaining positive by QMFF and POCT-ICT diminished 70% and 46%, respectively, after each MDA round. There was a significant annual drop in CFA (-0.290 OD) and IgG4 antibodies titres (-0.303 OD). This study provides evidence that MDA with DEC alone can be effective in the elimination of LF in Brazil.
Collapse
Affiliation(s)
- Jennifer S. F. da Silva
- Oswaldo Cruz Fundation, Aggeu Magalhães Institute, National Center of Lymphatic Filariasis, Recife, Pernambuco, Brazil
| | - Cynthia Braga
- Oswaldo Cruz Fundation, Aggeu Magalhães Institute, National Center of Lymphatic Filariasis, Recife, Pernambuco, Brazil
| | | | - Paula Oliveira
- Oswaldo Cruz Fundation, Aggeu Magalhães Institute, National Center of Lymphatic Filariasis, Recife, Pernambuco, Brazil
| | - Carlos Feitosa Luna
- Oswaldo Cruz Fundation, Aggeu Magalhães Institute, National Center of Lymphatic Filariasis, Recife, Pernambuco, Brazil
| | - Márcia Marcondes
- Municipal Health Secretariat of Recife, Recife, Pernambuco, Brazil
| | - Josué Araújo
- Oswaldo Cruz Fundation, Aggeu Magalhães Institute, National Center of Lymphatic Filariasis, Recife, Pernambuco, Brazil
| | - Maria Rosangela Grilis
- Oswaldo Cruz Fundation, Aggeu Magalhães Institute, National Center of Lymphatic Filariasis, Recife, Pernambuco, Brazil
| | | | - Eduardo Brandão
- Oswaldo Cruz Fundation, Aggeu Magalhães Institute, National Center of Lymphatic Filariasis, Recife, Pernambuco, Brazil
| | - Abraham Rocha
- Oswaldo Cruz Fundation, Aggeu Magalhães Institute, National Center of Lymphatic Filariasis, Recife, Pernambuco, Brazil
- Laboratory of the Hospital Otávio de Freitas, Recife, Pernambuco, Brazil
| |
Collapse
|
20
|
Saeed M, Faisal SM, Ahmad I, Kausar MA, Alam MJ, Khan S, Mustafa H. Status of lymphatic filariasis with progression of age and gender & eradication strategies: A survey among residents of Hardoi district of Uttar Pradesh, an endemic region of North India. Cell Mol Biol (Noisy-le-grand) 2018; 64:46-51. [PMID: 29642988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2017] [Revised: 01/30/2018] [Accepted: 03/07/2018] [Indexed: 06/08/2023]
Abstract
Lymphatic filariasis (LF) is a chronic and debilitating disease that affects people in tropical and sub-tropical areas of Asia, Africa, and Western Pacific. It is one of the leading community health problems in some of the endemic districts in India including Hardoi district of Uttar Pradesh. The disease is caused by the parasites Wuchereria bancrofti (W. bancrofti), Brugia malayi (B. malayi) and Brugia timori (B. timori), transmitted by the vector Culex, Anopheles and other mosquitoes. This cross-sectional survey study was carried out in rural areas, where its inhabitants vary in socio-economic status, from low to middle-income class. 12 villages of Hardoi district, Uttar Pradesh, India were included. The aim was to see the impact of age and gender on various clinical forms of LF and in estimating its economic and social implications. 260 LF affected people in different parts of Hardoi district were surveyed. The results revealed that the Mass Drug Administration (MDA) coverage reached more than 90%. The overall Microfilaria rate had been reduced, however the prevalence of elephantiasis increased with the progression of age and was found to be highest among people of >70 years of age, regardless of their gender.
Collapse
Affiliation(s)
- Mohd Saeed
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hail, Hail, KSA
| | - Syed Mohd Faisal
- Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, UP-202002, India
| | - Irfan Ahmad
- Department of Clinical Laboratory Science, College of Applied Medical Sciences, King Khalid University, Abha, KSA
| | - Mohd Adnan Kausar
- Department of Biochemistry, College of Medicine, University of Hail, Hail, KSA
| | - Md Jahoor Alam
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hail, Hail, KSA
| | - Saif Khan
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hail, Hail, KSA
| | - Huma Mustafa
- Council of Science and Technology, Lucknow, UP, India
| |
Collapse
|
21
|
Won KY, Robinson K, Hamlin KL, Tufa J, Seespesara M, Wiegand RE, Gass K, Kubofcik J, Nutman TB, Lammie PJ, Fuimaono S. Comparison of antigen and antibody responses in repeat lymphatic filariasis transmission assessment surveys in American Samoa. PLoS Negl Trop Dis 2018. [PMID: 29522520 PMCID: PMC5862496 DOI: 10.1371/journal.pntd.0006347] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Background Current WHO recommendations for lymphatic filariasis (LF) surveillance advise programs to implement activities to monitor for new foci of transmission after stopping mass drug administration (MDA). A current need in the global effort to eliminate LF is to standardize diagnostic tools and surveillance activities beyond the recommended transmission assessment survey (TAS). Methodology TAS was first conducted in American Samoa in 2011 (TAS 1) and a repeat TAS was carried out in 2015 (TAS 2). Circulating filarial antigen (CFA) and serologic results from both surveys were analyzed to determine whether interruption of LF transmission has been achieved in American Samoa. Principal findings A total of 1,134 and 864 children (5–10 years old) were enrolled in TAS 1 and TAS 2, respectively. Two CFA-positive children were identified in TAS 1, and one CFA-positive child was identified in TAS 2. Results of both surveys were below the threshold for which MDA was warranted. Additionally, 1,112 and 836 dried blood spots from TAS 1 and TAS 2, respectively were tested for antibodies to Wb123, Bm14 and Bm33 by luciferase immunoprecipitation system (LIPS) assay and multiplex bead assay. In 2011, overall prevalence of responses to Wb123, Bm14, and Bm33 was 1.0%, 6.8% and 12.0%, respectively. In 2015, overall prevalence of positive Bm14 and Bm33 responses declined significantly to 3.0% (p<0.001) and 7.8% (p = 0.013), respectively. Conclusions/Significance Although passing TAS 1 and TAS 2 and an overall decline in the prevalence of antibodies to Bm14 and Bm33 between these surveys suggests decreased exposure and infection among young children, there were persistent responses in some schools. Clustering and persistence of positive antibody responses in schools may be an indication of ongoing transmission. There is a need to better understand the limitations of current antibody tests, but our results suggest that serologic tools can have a role in guiding programmatic decision making. Lymphatic filariasis (LF), endemic in 72 countries, is a debilitating mosquito-transmitted parasitic disease caused by filarial worms. The Global Program to Eliminate Lymphatic Filariasis (GPELF) aims to interrupt transmission through mass drug administration (MDA) and to reduce suffering caused by the disease. At the start of GPELF in 2000 it was estimated that approximately 1.4 billion people were at risk for infection. By the end of 2016, primarily through successful MDA programs, the global number of people requiring interventions was reduced to 856.4 million. Current recommendations by the World Health Organization for LF surveillance advise programs to implement activities to monitor for new foci of transmission after stopping MDA. A current need in the global effort to eliminate LF is to standardize diagnostic tools and surveillance activities beyond the recommended transmission assessment survey (TAS). Two TAS were conducted in American Samoa; first in 2011 (TAS 1) and repeated in 2015 (TAS 2). In our evaluation, circulating filarial antigen and serologic results from both surveys were analyzed to determine whether interruption of LF transmission has been achieved in American Samoa. Despite passing TAS 1 and TAS 2, clustering and persistence of positive antibody responses in schools may be an indication of ongoing transmission. Results from our evaluation suggest that serologic tools can have a role in guiding programmatic decision-making.
Collapse
Affiliation(s)
- Kimberly Y. Won
- Centers for Disease Control and Prevention, Division of Parasitic Diseases and Malaria, Atlanta, GA, United States of America
- Swiss Tropical and Public Health Institute, Epidemiology and Public Health, Basel, Switzerland
- University of Basel, Tropical and Public Health Sciences, Basel, Switzerland
- * E-mail:
| | - Keri Robinson
- Centers for Disease Control and Prevention, Division of Parasitic Diseases and Malaria, Atlanta, GA, United States of America
| | - Katy L. Hamlin
- Centers for Disease Control and Prevention, Division of Parasitic Diseases and Malaria, Atlanta, GA, United States of America
| | - Joseph Tufa
- Department of Health, Lymphatic Filariasis Elimination Program, Pago Pago, American Samoa
| | - Margaret Seespesara
- Department of Health, Lymphatic Filariasis Elimination Program, Pago Pago, American Samoa
| | - Ryan E. Wiegand
- Centers for Disease Control and Prevention, Division of Parasitic Diseases and Malaria, Atlanta, GA, United States of America
| | - Katherine Gass
- Task Force for Global Health, Neglected Tropical Diseases Support Center, Decatur, GA, United States of America
| | - Joseph Kubofcik
- National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States of America
| | - Thomas B. Nutman
- National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States of America
| | - Patrick J. Lammie
- Centers for Disease Control and Prevention, Division of Parasitic Diseases and Malaria, Atlanta, GA, United States of America
- Task Force for Global Health, Neglected Tropical Diseases Support Center, Decatur, GA, United States of America
| | - Saipale Fuimaono
- Department of Health, Lymphatic Filariasis Elimination Program, Pago Pago, American Samoa
| |
Collapse
|
22
|
Rao RU, Samarasekera SD, Nagodavithana KC, Dassanayaka TDM, Punchihewa MW, Ranasinghe USB, Weil GJ. Reassessment of areas with persistent Lymphatic Filariasis nine years after cessation of mass drug administration in Sri Lanka. PLoS Negl Trop Dis 2017; 11:e0006066. [PMID: 29084213 PMCID: PMC5679644 DOI: 10.1371/journal.pntd.0006066] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2017] [Revised: 11/09/2017] [Accepted: 10/24/2017] [Indexed: 12/02/2022] Open
Abstract
Background Sri Lanka was one of the first countries to initiate a lymphatic filariasis (LF) elimination program based on WHO guidelines. The Anti-Filariasis Campaign provided 5 annual rounds of mass drug administration (MDA) with diethylcarbamazine plus albendazole in all 8 endemic districts from 2002–2006. Microfilaremia (Mf) prevalences have been consistently <1% in all sentinel and spot-check sites since 2006, and all evaluation units passed school-based transmission assessment surveys (TAS) in 2013. We previously reported results from comprehensive surveillance studies conducted in 2011–2013 that documented low-level persistence of Wuchereria bancrofti in 19 high risk areas in 8 endemic districts. We now present results from repeat surveys conducted 3 to 4 years later in 6 areas that had the strongest LF signals in the prior study. Methodology and principal findings The surveys assessed prevalence of filarial antigenemia (CFA) and Mf in communities, CFA and anti-filarial antibody in school children (ages 6–8), and filarial DNA in Culex mosquitoes (molecular xenomonitoring, MX). Three study areas had significantly improved infection parameters compared to the prior study, but three other areas had little change. MX was more sensitive for detecting W. bancrofti persistence, and it was a better predictor than other parameters. Adult males accounted for more than 80% of infections detected in the study. Conclusions These results suggest that W. bancrofti transmission was near the break point in some of the areas studied in 2011–13. LF is likely to decline to zero without further intervention in these areas, while other areas may require further intervention. Long term surveillance may be needed to verify W. bancrofti elimination in areas like Sri Lanka with efficient transmission by Culex. Test and treat or other programs targeting adult males plus bed net promotion may be more effective than MDA for clearing remaining hotspots of transmission in Sri Lanka. Lymphatic Filariasis (LF, also known as “elephantiasis”) is a disabling and deforming tropical disease caused by parasitic worms that are transmitted by mosquitoes. The Sri Lankan Anti-Filariasis Campaign provided 5 annual rounds of mass drug administration (MDA) with diethylcarbamazine and albendazole between 2002 and 2006 in all endemic areas, and this reduced infection prevalence to very low levels. Post-MDA surveillance conducted by our group in 19 sentinel sites in 8 endemic districts in 2011–2013 revealed evidence of persistent LF infection in all study sites. The present paper reports results of repeat assessments conducted 3–4 years later in 6 areas with high signals in the prior study. LF parameters were significantly improved in 3 areas where LF appears to be on a glide path to elimination. However, LF infection parameters remained high in 3 areas, and further work will probably be required to interrupt transmission in these areas. Molecular xenomonitoring (to detect filarial DNA in mosquito vectors) was especially sensitive for detecting persistent LF in Sri Lanka, and this may also be true in other areas with Culex transmission. Our results suggest that test and treat or other programs targeting adult males plus expanded bed net use may be helpful for clearing up remaining LF hotspots.
Collapse
Affiliation(s)
- Ramakrishna U. Rao
- Washington University School of Medicine, St. Louis, MO, United States of America
- * E-mail:
| | | | | | | | | | | | - Gary J. Weil
- Washington University School of Medicine, St. Louis, MO, United States of America
| |
Collapse
|
23
|
de Souza DK, Ahorlu CS, Adu-Amankwah S, Otchere J, Mensah SK, Larbi IA, Mensah GE, Biritwum NK, Boakye DA. Community-based trial of annual versus biannual single-dose ivermectin plus albendazole against Wuchereria bancrofti infection in human and mosquito populations: study protocol for a cluster randomised controlled trial. Trials 2017; 18:448. [PMID: 28969715 PMCID: PMC5625710 DOI: 10.1186/s13063-017-2196-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2017] [Accepted: 09/14/2017] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND The Global Programme for the Elimination of Lymphatic Filariasis (GPELF) has been in operation since the year 2000, with the aim of eliminating the disease by the year 2020, following five to six rounds of effective annual mass drug administration (MDA). The treatment regimen is ivermectin (IVM) in combination with diethylcarbamazine (DEC) or albendazole (ALB). In Ghana, MDA has been undertaken since 2001. While the disease has been eliminated in many areas, transmission has persisted in some implementation units that had experienced 15 or more rounds of MDA. Thus, new intervention strategies could eliminate residual infection in areas of persistent transmission and speed up the lymphatic filariasis (LF)-elimination process. This study, therefore, seeks to test the hypothesis that biannual treatment of LF-endemic communities will accelerate the interruption of LF in areas of persistent transmission. METHODS A cluster randomised trial will be implemented in LF-endemic communities in Ghana. The interventions will be yearly or twice-yearly MDA delivered to entire endemic communities. Allocation to study group will be by clusters identified using the prevalence of LF. Clusters will be randomised to one of two groups: receiving either (1) annual treatment with IVM + ALB or (2) annual MDA with IVM + ALB, followed by an additional MDA 6 months later. The primary outcome measure is the prevalence of LF infection, assessed by four cross-sectional surveys. Entomological assessments will also be undertaken to evaluate the transmission intensity of the disease in the study clusters. Costs and cost-effectiveness will be evaluated. Among a random subsample of participants, microfilaria prevalence will be assessed longitudinally. A nested process evaluation, using semi-structured interviews, focus group discussions and a stakeholder analysis, will investigate the community acceptability, feasibility and scale-up of each delivery system. DISCUSSION It is expected that this study will add to the existing evidence on the need for alternative intervention strategies for the elimination of LF in Ghana and in other African countries that are facing similar challenges or are at the beginning of their LF-elimination programmes. TRIAL REGISTRATION ClinicalTrials.gov, ID: NCT03036059 . Registered on 26 January 2017. Pan African Clinical Trials Registry, ID: PACTR201702002012425 . Registered on 23 February 2017.
Collapse
Affiliation(s)
- Dziedzom K. de Souza
- Department of Parasitology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon-Accra, Ghana
| | - Collins S. Ahorlu
- Department of Epidemiology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon-Accra, Ghana
| | - Susan Adu-Amankwah
- Department of Epidemiology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon-Accra, Ghana
| | - Joseph Otchere
- Department of Parasitology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon-Accra, Ghana
| | - Sedzro K. Mensah
- Department of Epidemiology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon-Accra, Ghana
| | - Irene A. Larbi
- Department of Epidemiology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon-Accra, Ghana
| | - George E. Mensah
- Department of Epidemiology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon-Accra, Ghana
| | | | - Daniel A. Boakye
- Department of Parasitology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon-Accra, Ghana
| |
Collapse
|
24
|
Modi A, Gamit S, Jesalpura BS, Kurien G, Kosambiya JK. Reaching endpoints for lymphatic filariasis elimination- results from mass drug administration and nocturnal blood surveys, South Gujarat, India. PLoS Negl Trop Dis 2017; 11:e0005476. [PMID: 28369129 PMCID: PMC5391126 DOI: 10.1371/journal.pntd.0005476] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2016] [Revised: 04/13/2017] [Accepted: 03/10/2017] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Following the World Health Assembly resolution on Elimination of lymphatic filariasis (ELF) as a public health problem by the year 2020, a Global Program (GPELF) was launched in 1997 to help endemic countries to initiate national programs. The current strategy to interrupt transmission of LF, is administration of once-yearly, single-dose, two-drug regimen (Albendazole with Diethylcarbamazine (DEC) to be used in endemic areas with the goal of reaching 65% epidemiological coverage for 4-6 years. We report findings of independent assessment from year 2010 to 2015 for last six rounds, after initial five rounds of Mass Drug Administration (MDA) since 2005 for ELF in endemic area of Gujarat. METHODS Independent assessment of MDA was performed to find coverage and compliance indicators, reasons for non-coverage and non-compliance in five Implementation Units (IUs). Pre, during and post MDA evaluations were done in three phases. The impact of MDA was measured by microfilaraemia survey. A total of eight sites, four random and four fixed sentinel sites were selected to calculate microfilaria rate (MF) per IUs per year. In years 2010 to 2015, we report results from 125,936 nocturnal blood smears and 17551 population in 120 selected clusters. Four clusters were selected per year in each of the five IUs for assessment of MDA round. RESULT Post MDA survey showed drug coverage between 81%-88% and epidemiological coverage 77%-89% across years. Main reasons for non-coverage were drug administrator related (the team did not visit or missed people) while non-compliance was population related (fear of side effects, sickness, people forgot or absent). During MDA findings show that the directly observed consumption is considerably improved from 58% in 2010 to 82% in 2015. The knowledge about benefits of drug provided also increased from 59% to 90% over the years. The current MF rate is less than one in all IUs with an overall 68% percent decrease from baseline year 2005 to year 2015. The average MF rate of Gujarat is 0.44 for year 2015. CONCLUSIONS The findings show that achieving adequate epidemiological and drug coverage is possible by actual field level operation of the program in large endemic areas. The results and feedback from independent assessment, performed regularly, could guide the policymakers and program managers for mid-term corrections and to frame strategies to enhance program. Monitoring of coverage and impact indicator together informs decisions for reaching end-point of MDA. The impact indicator- microfilaria rate in all IUs of South Gujarat Region has reached and remained less than one percent signaling end-points of MDA. Post MDA stringent monitoring in form of TAS is recommended to keep vigil on maintenance of elimination achieved.
Collapse
Affiliation(s)
- Anjali Modi
- Department of Community Medicine, Government Medical College, Surat, Gujarat, India
| | - Sukesha Gamit
- Department of Community Medicine, Government Medical College, Surat, Gujarat, India
| | - Bharat S. Jesalpura
- National Vector Borne Disease Control Department (NVBDCP), Health and Family Welfare Department, Government of Gujarat, Gandhinagar, Gujarat, India
| | - George Kurien
- National Vector Borne Disease Control Department (NVBDCP), Health and Family Welfare Department, Government of Gujarat, Gandhinagar, Gujarat, India
| | | |
Collapse
|
25
|
Aljayyoussi G, Tyrer HE, Ford L, Sjoberg H, Pionnier N, Waterhouse D, Davies J, Gamble J, Metuge H, Cook DAN, Steven A, Sharma R, Guimaraes AF, Clare RH, Cassidy A, Johnston KL, Myhill L, Hayward L, Wanji S, Turner JD, Taylor MJ, Ward SA. Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis. Sci Rep 2017; 7:210. [PMID: 28303006 PMCID: PMC5428297 DOI: 10.1038/s41598-017-00322-5] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2016] [Accepted: 02/21/2017] [Indexed: 12/29/2022] Open
Abstract
Lymphatic filariasis (LF) and onchocerciasis are priority neglected tropical diseases targeted for elimination. The only safe drug treatment with substantial curative activity against the filarial nematodes responsible for LF (Brugia malayi, Wuchereria bancrofti) or onchocerciasis (Onchocerca volvulus) is doxycycline. The target of doxycycline is the essential endosymbiont, Wolbachia. Four to six weeks doxycycline therapy achieves >90% depletion of Wolbachia in worm tissues leading to blockade of embryogenesis, adult sterility and premature death 18-24 months post-treatment. Long treatment length and contraindications in children and pregnancy are obstacles to implementing doxycycline as a public health strategy. Here we determine, via preclinical infection models of Brugia malayi or Onchocerca ochengi that elevated exposures of orally-administered rifampicin can lead to Wolbachia depletions from filariae more rapidly than those achieved by doxycycline. Dose escalation of rifampicin achieves >90% Wolbachia depletion in time periods of 7 days in B. malayi and 14 days in O. ochengi. Using pharmacokinetic-pharmacodynamic modelling and mouse-human bridging analysis, we conclude that clinically relevant dose elevations of rifampicin, which have recently been determined as safe in humans, could be administered as short courses to filariasis target populations with potential to reduce anti-Wolbachia curative therapy times to between one and two weeks.
Collapse
Affiliation(s)
- Ghaith Aljayyoussi
- Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
| | - Hayley E Tyrer
- Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
| | - Louise Ford
- Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
| | - Hanna Sjoberg
- Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
| | - Nicolas Pionnier
- Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
| | - David Waterhouse
- Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
| | - Jill Davies
- Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
| | - Joanne Gamble
- Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
| | - Haelly Metuge
- Research Foundation in Tropical Medicine and the Environment, Buea, Cameroon
- Department of Microbiology and Parasitology, University of Buea, Buea, Cameroon
| | - Darren A N Cook
- Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
| | - Andrew Steven
- Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
| | - Raman Sharma
- Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
| | - Ana F Guimaraes
- Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
| | - Rachel H Clare
- Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
| | - Andrew Cassidy
- Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
| | - Kelly L Johnston
- Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
| | - Laura Myhill
- Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
| | - Laura Hayward
- Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
| | - Samuel Wanji
- Research Foundation in Tropical Medicine and the Environment, Buea, Cameroon
- Department of Microbiology and Parasitology, University of Buea, Buea, Cameroon
| | - Joseph D Turner
- Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
| | - Mark J Taylor
- Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK.
| | - Stephen A Ward
- Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
| |
Collapse
|
26
|
Mengistu B, Deribe K, Kebede F, Martindale S, Hassan M, Sime H, Mackenzie C, Mulugeta A, Tamiru M, Sileshi M, Hailu A, Gebre T, Fentaye A, Kebede B. The National Programme to Eliminate Lymphatic Filariasis from Ethiopia. Ethiop Med J 2017; 55:45-54. [PMID: 28878429 PMCID: PMC5582637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Lymphatic filariasis (LF) is one of the most debilitating and disfiguring diseases common in Ethiopia and is caused by Wuchereria bancrofti. Mapping for LF has shown that 70 woredas (districts) are endemic and 5.9 million people are estimated to be at risk. The national government's LF elimination programme commenced in 2009 in 5 districts integrated with the onchocerciasis programme. The programme developed gradually and has shown significant progress over the past 6 years, reaching 100% geographical coverage for mass drug administration (MDA) by 2016. To comply with the global LF elimination goals an integrated morbidity management and disability prevention (MMDP) guideline and a burden assessment programme has also been developed; MMDP protocols and a hydrocoele surgical handbook produced for country-wide use. In Ethiopia, almost all LF endemic districts are co-endemic with malaria and vector control aspects of the activities are conducted in the context of malaria programme as the vectors for both diseases are mosquitoes. In order to monitor the elimination, 11 sentinel and spot-check sites have been established and baseline information has been collected. Although significant achievements have been achieved in the scale up of the LF elimination programme, there is still a need to strengthen operational research to generate programme-relevant evidence, to increase access to morbidity management services, and to improve monitoring and evaluation of the LF programme. However, the current status of implementation of the LF national programme indicates that Ethiopia is poised to achieve the 2020 goal of elimination of LF. Nevertheless, to achieve this goal, high and sustained treatment coverage and strong monitoring and evaluation of the programme are essential.
Collapse
Affiliation(s)
| | - Kebede Deribe
- Federal Ministry of Health, Addis Ababa, Ethiopia
- Wellcome Trust Brighton & Sussex Centre for Global Health Research, Brighton & Sussex Medical School, Falmer, Brighton, UK
- School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia
- RTI International, Addis Ababa, Ethiopia
| | | | - Sarah Martindale
- Centre for Neglected Tropical Diseases (CNTD), Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
| | | | - Heven Sime
- Ethiopian Public Health Institute, Addis Ababa, Ethiopia
| | - Charles Mackenzie
- Centre for Neglected Tropical Diseases (CNTD), Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK
| | - Abate Mulugeta
- World Health Organization, Menelik Avenue, UNECA compound, P.O. Box 3069, Addis Ababa, Ethiopia
| | | | - Mesfin Sileshi
- Federal Ministry of Health, Addis Ababa, Ethiopia
- RTI International, Addis Ababa, Ethiopia
| | - Asrat Hailu
- School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia
| | - Teshome Gebre
- International Trachoma Initiative, Addis Ababa, Ethiopia
| | - Amha Fentaye
- Federal Ministry of Health, Addis Ababa, Ethiopia
| | | |
Collapse
|
27
|
Kroidl I, Saathof E, Maganga L, Clowes P, Maboko L, Hoerauf A, Makunde WH, Haule A, Mviombo P, Pitter B, Mgeni N, Mabuye J, Kowuor D, Mwingira U, Malecela MN, Löscher T, Hoelscher M. Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania. PLoS Negl Trop Dis 2016; 10:e0004618. [PMID: 27070786 PMCID: PMC4829227 DOI: 10.1371/journal.pntd.0004618] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2015] [Accepted: 03/18/2016] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Annual mass treatment with ivermectin and albendazole is used to treat lymphatic filariasis in many African countries, including Tanzania. In areas where both diseases occur, it is unclear whether HIV co-infection reduces treatment success. METHODOLOGY In a general population study in Southwest Tanzania, individuals were tested for HIV and circulating filarial antigen, an indicator of Wuchereria bancrofti adult worm burden, before the first and after 2 consecutive rounds of anti-filarial mass drug administration. PRINCIPLE FINDINGS Testing of 2104 individuals aged 0-94 years before anti-filarial treatment revealed a prevalence of 24.8% for lymphatic filariasis and an HIV-prevalence of 8.9%. Lymphatic filariasis was rare in children, but prevalence increased in individuals above 10 years, whereas a strong increase in HIV was only seen above 18 years of age. The prevalence of lymphatic filariasis in adults above 18 years was 42.6% and 41.7% (p = 0.834) in HIV-negatives and-positives, respectively. Similarly, the HIV prevalence in the lymphatic filariasis infected (16.6%) and uninfected adult population (17.1%) was nearly the same. Of the above 2104 individuals 798 were re-tested after 2 rounds of antifilarial treatment. A significant reduction in the prevalence of circulating filarial antigen from 21.6% to 19.7% was found after treatment (relative drop of 8.8%, McNemar's exact p = 0.036). Furthermore, the post-treatment reduction of CFA positivity was (non-significantly) larger in HIV-positives than in HIV-negatives (univariable linear regression p = 0.154). CONCLUSION/SIGNIFICANCE In an area with a high prevalence for both diseases, no difference was found between HIV-infected and uninfected individuals regarding the initial prevalence of lymphatic filariasis. A moderate but significant reduction in lymphatic filariasis prevalence and worm burden was demonstrated after two rounds of treatment with albendazole and ivermectin. Treatment effects were more pronounced in the HIV co-infected subgroup, indicating that the effectiveness of antifilarial treatment was not reduced by concomitant HIV-infection. Studies with longer follow-up time could validate the observed differences in treatment effectiveness.
Collapse
Affiliation(s)
- Inge Kroidl
- Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Munich, Germany
- National Institute of Medical Research (NIMR)-Mbeya Medical Research Centre (MMRC), Mbeya, Tanzania
- * E-mail:
| | - Elmar Saathof
- Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Munich, Germany
- German Center for Infection Research (DZIF), Munich, Germany
| | - Lucas Maganga
- National Institute of Medical Research (NIMR)-Mbeya Medical Research Centre (MMRC), Mbeya, Tanzania
| | - Petra Clowes
- Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Munich, Germany
- National Institute of Medical Research (NIMR)-Mbeya Medical Research Centre (MMRC), Mbeya, Tanzania
| | - Leonard Maboko
- National Institute of Medical Research (NIMR)-Mbeya Medical Research Centre (MMRC), Mbeya, Tanzania
| | - Achim Hoerauf
- German Center for Infection Research (DZIF), Bonn-Cologne, Germany
- Institute of Medical Microbiology, Immunology and Parasitology, Bonn, Germany
| | | | - Antelmo Haule
- National Institute of Medical Research (NIMR)-Mbeya Medical Research Centre (MMRC), Mbeya, Tanzania
| | - Prisca Mviombo
- National Institute of Medical Research (NIMR)-Mbeya Medical Research Centre (MMRC), Mbeya, Tanzania
| | - Bettina Pitter
- Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Munich, Germany
- National Institute of Medical Research (NIMR)-Mbeya Medical Research Centre (MMRC), Mbeya, Tanzania
| | - Neema Mgeni
- National Institute of Medical Research (NIMR)-Mbeya Medical Research Centre (MMRC), Mbeya, Tanzania
| | - Joseph Mabuye
- National Institute of Medical Research (NIMR)-Mbeya Medical Research Centre (MMRC), Mbeya, Tanzania
| | - Dickens Kowuor
- National Institute of Medical Research (NIMR)-Mbeya Medical Research Centre (MMRC), Mbeya, Tanzania
| | - Upendo Mwingira
- National Institute of Medical Research (NIMR), Dar es Salaam, Tanzania
| | | | - Thomas Löscher
- Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Munich, Germany
| | - Michael Hoelscher
- Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Munich, Germany
- National Institute of Medical Research (NIMR)-Mbeya Medical Research Centre (MMRC), Mbeya, Tanzania
- German Center for Infection Research (DZIF), Munich, Germany
| |
Collapse
|
28
|
Khan AM, Dutta P, Sarmah CK, Baruah NK, Das S, Pathak AK, Sarmah P, Hussain ME, Mahanta J. Prevalence of lymphatic filariasis in a tea garden worker population of Dibrugarh (Assam), India after six rounds of mass drug administration. J Vector Borne Dis 2015; 52:314-320. [PMID: 26714512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023] Open
Abstract
BACKGROUND & OBJECTIVES Lymphatic filariasis (LF) is endemic in the state of Assam and mass drug administration (MDA) programme for LF elimination is being implemented in the state since 2004. A study on prevalence of microfilaria (mf), disease endemicity and vector infection was carried out in a tea garden population of Dibrugarh, Assam (India) to assess the effect of ongoing MDA programme on elimination of LF. METHODS Finger prick thick blood smears (20 mm3) were made from individuals aged ≥2 yr old during night blood survey in between 2000-0000 hrs during the period of November 2012 to February 2013. Blood smears were dehaemoglobinised, stained with Giemsa and examined under microscope for presence of mf. Indoor resting mosquitoes were collected during 0600-1000 hrs and female Culex quinquefasciatus were dissected and examined under microscope for larval forms of the parasite. RESULTS A total of 634 blood smears were collected and screened for mf and 47 (7.41%) individuals were found microfilaraemic, with predominance of males (74.5%). Highest mf rate (20.0%) was seen in the males of 30-39 yr age group while in females, age group of 10-19 yr recorded maximum mf rate (5.48%). Entomological collection and dissection of Cx. quinquefasciatus revealed presence of larval stages of the parasite and infection and infectivity rates recorded were 13.20 and 3.70%, respectively. Chronic clinical manifestations in the form of elephantiasis and hydrocele were recorded in 33 (5.73%) subjects of the 575 examined. INTERPRETATION & CONCLUSION Mass drug administration data showed six rounds of MDA with drug distribution coverage in between 63.42 and 95.93% in the study population. Out of 634 individuals examined 47 were found microfilaraemic giving an overall infection rate of 7.41%. Mosquito vector infection and infectivity rates were 13.20 and 3.70%, respectively. Presence of high mf rate, vector infectivity rate and clinical cases in the study population after six rounds of MDA warrants concerted efforts to be made for effective implementation and monitoring of MDA for success of LF elimination programme.
Collapse
Affiliation(s)
- A M Khan
- Regional Medical Research Centre, Northeastern Region (ICMR), Dibrugarh, Assam, India
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Coulibaly YI, Dembele B, Diallo AA, Konaté S, Dolo H, Coulibaly SY, Doumbia SS, Soumaoro L, Coulibaly ME, Bockarie MJ, Molyneux D, Nutman TB, Klion AD, Toure YT, Traore SF. The Impact of Six Annual Rounds of Mass Drug Administration on Wuchereria bancrofti Infections in Humans and in Mosquitoes in Mali. Am J Trop Med Hyg 2015; 93:356-60. [PMID: 26033027 PMCID: PMC4530761 DOI: 10.4269/ajtmh.14-0516] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2014] [Accepted: 02/16/2015] [Indexed: 11/07/2022] Open
Abstract
Wuchereria bancrofti prevalence and transmission were assessed in six endemic villages in Sikasso, Mali prior to and yearly during mass drug administration (MDA) with albendazole and ivermectin from 2002 to 2007. Microfilaremia was determined by calibrated thick smear of night blood in adult volunteers and circulating filarial antigen was measured using immunochromatographic card test in children < 5 years of age. Mosquitoes were collected by human landing catch from July to December. None of the 686 subjects tested were microfilaremic 12 months after the sixth MDA round. More importantly, circulating antigen was not detected in any of the 120 children tested, as compared with 53% (103/194) before the institution of MDA. The number of infective bites/human/year decreased from 4.8 in 2002 to 0.04 in 2007, and only one mosquito containing a single infective larva was observed 12 months after the final MDA round. Whether this dramatic reduction in transmission will be sustained following cessation of MDA remains to be seen.
Collapse
Affiliation(s)
- Yaya I Coulibaly
- International Center of Excellence in Research (ICER-Mali), Filariasis Research and Training Unit, Bamako, Mali; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; National Institutes of Health, Laboratory of Parasitic Diseases, Helminth Immunology Section, Bethesda, Maryland; National Institutes of Health, Laboratory of Parasitic Diseases, Eosinophil Pathology Section, Bethesda, Maryland; World Health Organization, Vectors, Environment and Society Research, Geneva, Switzerland
| | - Benoit Dembele
- International Center of Excellence in Research (ICER-Mali), Filariasis Research and Training Unit, Bamako, Mali; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; National Institutes of Health, Laboratory of Parasitic Diseases, Helminth Immunology Section, Bethesda, Maryland; National Institutes of Health, Laboratory of Parasitic Diseases, Eosinophil Pathology Section, Bethesda, Maryland; World Health Organization, Vectors, Environment and Society Research, Geneva, Switzerland
| | - Abdallah Amadou Diallo
- International Center of Excellence in Research (ICER-Mali), Filariasis Research and Training Unit, Bamako, Mali; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; National Institutes of Health, Laboratory of Parasitic Diseases, Helminth Immunology Section, Bethesda, Maryland; National Institutes of Health, Laboratory of Parasitic Diseases, Eosinophil Pathology Section, Bethesda, Maryland; World Health Organization, Vectors, Environment and Society Research, Geneva, Switzerland
| | - Siaka Konaté
- International Center of Excellence in Research (ICER-Mali), Filariasis Research and Training Unit, Bamako, Mali; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; National Institutes of Health, Laboratory of Parasitic Diseases, Helminth Immunology Section, Bethesda, Maryland; National Institutes of Health, Laboratory of Parasitic Diseases, Eosinophil Pathology Section, Bethesda, Maryland; World Health Organization, Vectors, Environment and Society Research, Geneva, Switzerland
| | - Houseini Dolo
- International Center of Excellence in Research (ICER-Mali), Filariasis Research and Training Unit, Bamako, Mali; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; National Institutes of Health, Laboratory of Parasitic Diseases, Helminth Immunology Section, Bethesda, Maryland; National Institutes of Health, Laboratory of Parasitic Diseases, Eosinophil Pathology Section, Bethesda, Maryland; World Health Organization, Vectors, Environment and Society Research, Geneva, Switzerland
| | - Siaka Yamoussa Coulibaly
- International Center of Excellence in Research (ICER-Mali), Filariasis Research and Training Unit, Bamako, Mali; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; National Institutes of Health, Laboratory of Parasitic Diseases, Helminth Immunology Section, Bethesda, Maryland; National Institutes of Health, Laboratory of Parasitic Diseases, Eosinophil Pathology Section, Bethesda, Maryland; World Health Organization, Vectors, Environment and Society Research, Geneva, Switzerland
| | - Salif Seriba Doumbia
- International Center of Excellence in Research (ICER-Mali), Filariasis Research and Training Unit, Bamako, Mali; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; National Institutes of Health, Laboratory of Parasitic Diseases, Helminth Immunology Section, Bethesda, Maryland; National Institutes of Health, Laboratory of Parasitic Diseases, Eosinophil Pathology Section, Bethesda, Maryland; World Health Organization, Vectors, Environment and Society Research, Geneva, Switzerland
| | - Lamine Soumaoro
- International Center of Excellence in Research (ICER-Mali), Filariasis Research and Training Unit, Bamako, Mali; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; National Institutes of Health, Laboratory of Parasitic Diseases, Helminth Immunology Section, Bethesda, Maryland; National Institutes of Health, Laboratory of Parasitic Diseases, Eosinophil Pathology Section, Bethesda, Maryland; World Health Organization, Vectors, Environment and Society Research, Geneva, Switzerland
| | - Michel Emmanuel Coulibaly
- International Center of Excellence in Research (ICER-Mali), Filariasis Research and Training Unit, Bamako, Mali; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; National Institutes of Health, Laboratory of Parasitic Diseases, Helminth Immunology Section, Bethesda, Maryland; National Institutes of Health, Laboratory of Parasitic Diseases, Eosinophil Pathology Section, Bethesda, Maryland; World Health Organization, Vectors, Environment and Society Research, Geneva, Switzerland
| | - Moses J Bockarie
- International Center of Excellence in Research (ICER-Mali), Filariasis Research and Training Unit, Bamako, Mali; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; National Institutes of Health, Laboratory of Parasitic Diseases, Helminth Immunology Section, Bethesda, Maryland; National Institutes of Health, Laboratory of Parasitic Diseases, Eosinophil Pathology Section, Bethesda, Maryland; World Health Organization, Vectors, Environment and Society Research, Geneva, Switzerland
| | - David Molyneux
- International Center of Excellence in Research (ICER-Mali), Filariasis Research and Training Unit, Bamako, Mali; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; National Institutes of Health, Laboratory of Parasitic Diseases, Helminth Immunology Section, Bethesda, Maryland; National Institutes of Health, Laboratory of Parasitic Diseases, Eosinophil Pathology Section, Bethesda, Maryland; World Health Organization, Vectors, Environment and Society Research, Geneva, Switzerland
| | - Thomas B Nutman
- International Center of Excellence in Research (ICER-Mali), Filariasis Research and Training Unit, Bamako, Mali; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; National Institutes of Health, Laboratory of Parasitic Diseases, Helminth Immunology Section, Bethesda, Maryland; National Institutes of Health, Laboratory of Parasitic Diseases, Eosinophil Pathology Section, Bethesda, Maryland; World Health Organization, Vectors, Environment and Society Research, Geneva, Switzerland
| | - Amy D Klion
- International Center of Excellence in Research (ICER-Mali), Filariasis Research and Training Unit, Bamako, Mali; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; National Institutes of Health, Laboratory of Parasitic Diseases, Helminth Immunology Section, Bethesda, Maryland; National Institutes of Health, Laboratory of Parasitic Diseases, Eosinophil Pathology Section, Bethesda, Maryland; World Health Organization, Vectors, Environment and Society Research, Geneva, Switzerland
| | - Yeya T Toure
- International Center of Excellence in Research (ICER-Mali), Filariasis Research and Training Unit, Bamako, Mali; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; National Institutes of Health, Laboratory of Parasitic Diseases, Helminth Immunology Section, Bethesda, Maryland; National Institutes of Health, Laboratory of Parasitic Diseases, Eosinophil Pathology Section, Bethesda, Maryland; World Health Organization, Vectors, Environment and Society Research, Geneva, Switzerland
| | - Sekou F Traore
- International Center of Excellence in Research (ICER-Mali), Filariasis Research and Training Unit, Bamako, Mali; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; University of Liverpool, Liverpool Liverpool School of Tropical Medicine, Centre for Neglected Tropical Diseases, Liverpool, United Kingdom; National Institutes of Health, Laboratory of Parasitic Diseases, Helminth Immunology Section, Bethesda, Maryland; National Institutes of Health, Laboratory of Parasitic Diseases, Eosinophil Pathology Section, Bethesda, Maryland; World Health Organization, Vectors, Environment and Society Research, Geneva, Switzerland
| |
Collapse
|
30
|
De Britto RL, Vanamail P, Sankari T, Vijayalakshmi G, Das LK, Pani SP. Enhanced efficacy of sequential administration of Albendazole for the clearance of Wuchereria bancrofti infection: Double blind RCT. Trop Biomed 2015; 32:198-209. [PMID: 26691247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Till today, there is no effective treatment protocol for the complete clearance of Wuchereria bancrofti (W.b) infection that causes secondary lymphoedema. In a double blind randomized control trial (RCT), 146 asymptomatic W. b infected individuals were randomly assigned to one of the four regimens for 12 days, DEC 300 mg + Doxycycline 100 mg coadministration or DEC 300 mg + Albendazole 400 mg co-administration or DEC 300 mg + Albendazole 400 mg sequential administration or control regimen DEC 300 mg and were followed up at 13, 26 and 52 weeks post-treatment for the clearance of infection. At intake, there was no significant variation in mf counts (F(3,137)=0.044; P=0.988) and antigen levels (F(3,137)=1.433; P=0.236) between the regimens. Primary outcome analysis showed that DEC + Albendazole sequential administration has an enhanced efficacy over DEC + Albendazole co-administration (80.6 Vs 64.7%), and this regimen is significantly different when compared to DEC + doxycycline co-administration and control (P<0.05), in clearing microfilaria in 13 weeks. Secondary outcome analysis showed that, all the trial regimens were comparable to control regimen in clearing antigen (F(3, 109)=0.405; P=0.750). Therefore, DEC + Albendazole sequential administration appears to be a better option for rapid clearance of W. b microfilariae in 13 weeks time. (Clinical trials.gov identifier - NCT02005653).
Collapse
Affiliation(s)
- R L De Britto
- Unit of Clinical Epidemiology & Chemotherapy, Vector Control Research Centre, Pondicherry, India
| | - P Vanamail
- All India Institute of Medical Sciences, New Delhi, India
| | - T Sankari
- Unit of Microbiology & Immunology, Vector Control Research Centre, Pondicherry, India
| | - G Vijayalakshmi
- Unit of Clinical Epidemiology & Chemotherapy, Vector Control Research Centre, Pondicherry, India
| | - L K Das
- Unit of Clinical Epidemiology & Chemotherapy, Vector Control Research Centre, Pondicherry, India
| | - S P Pani
- Faculty of Medicine, Quest International University Perak, Malaysia
| |
Collapse
|
31
|
|
32
|
Talaat KR, Babu S, Menon P, Kumarasamy N, Sharma J, Arumugam J, Dhakshinamurthy K, Srinivasan R, Poongulali S, Gu W, Fay MP, Swaminathan S, Nutman TB. Treatment of W. bancrofti (Wb) in HIV/Wb coinfections in South India. PLoS Negl Trop Dis 2015; 9:e0003622. [PMID: 25793933 PMCID: PMC4368731 DOI: 10.1371/journal.pntd.0003622] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2014] [Accepted: 02/13/2015] [Indexed: 11/30/2022] Open
Abstract
Background The disease course of human immunodeficiency virus (HIV) is often altered by existing or newly acquired coincident infections. Methodology/Principal Findings To assess the influence of pre-existing Wuchereria bancrofti infection on HIV progression, we performed a case-controlled treatment study of HIV positive individuals with (FIL+) or without (FIL-) W. bancrofti infection. Twenty-eight HIV+/FIL+ and 51 matched HIV+/FIL- subjects were treated with a single dose of diethylcarbamazine and albendazole (DEC/Alb) and followed for a year at regular intervals. Sixteen of the HIV+/FIL+ subjects (54%) and 28 of the HIV+/FIL- controls (57%) were on antiretroviral therapy (ART) during the study. Following treatment, no differences were noted in clinical outcomes between the 2 groups. There also was no significant difference between the groups in the HIV viral load at 12 months as a percentage of baseline viral load (HIV+/FIL+ group had on average 0.97 times the response of the HIV+/FIL- group, 95% CI 0.88, 1.07) between the groups. Furthermore, there were no significant differences found in either the change in viral load at 1, 3, or 6 months or in the change in CD4 count at 3, 6, or 12 months between the 2 groups. Conclusions/Significance We were unable to find a significant effect of W. bancrofti infection or its treatment on HIV clinical course or surrogate markers of HIV disease progression though we recognized that our study was limited by the smaller than predicted sample size and by the use of ART in half of the patients. Treatment of W. bancrofti coinfection in HIV positive subjects (as is usual in mass drug administration campaigns) did not represent an increased risk to the subjects, and should therefore be considered for PLWHA living in W. bancrofti endemic areas. Trial Registration ClinicalTrials.gov NCT00344279 In people living with HIV infection, simultaneous infections can adversely affect HIV disease. This has been seen with bacterial (tuberculosis), viral (cytomegalovirus), and parasitic infections (toxoplasmosis). Lymphatic filariasis is caused by a thin thread-like parasite that lives in the lymph vessels of infected people. It can cause significant disability. This infection is found in much of the same areas that high levels of HIV infection. We were interested in knowing if lymphatic filariasis changed the course of HIV infection in people with both diseases. In this study, the authors enrolled people in India who were living with HIV who either had or didn’t have filarial infection. All patients were treated for filariasis with 2 drugs, and then were followed for 1 year to see how their HIV disease progressed. No difference in HIV disease progression was found between the groups that did or did not have filariasis before treatment. The patients with HIV did well with the medicine for filariasis.
Collapse
Affiliation(s)
- Kawsar R. Talaat
- Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, United States of America
- Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America
- * E-mail:
| | - Subash Babu
- Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America
| | - Pradeep Menon
- National Institute for Research in Tuberculosis (formerly Tuberculosis Research Centre), Indian Council of Medical Research, Chennai, India
| | | | | | | | - Kalaivani Dhakshinamurthy
- National Institute for Research in Tuberculosis (formerly Tuberculosis Research Centre), Indian Council of Medical Research, Chennai, India
| | - Ramalingam Srinivasan
- National Institute for Research in Tuberculosis (formerly Tuberculosis Research Centre), Indian Council of Medical Research, Chennai, India
| | | | - Wenjuan Gu
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, United States of America
| | - Michael P. Fay
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, United States of America
| | - Soumya Swaminathan
- National Institute for Research in Tuberculosis (formerly Tuberculosis Research Centre), Indian Council of Medical Research, Chennai, India
| | - Thomas B. Nutman
- Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America
| |
Collapse
|
33
|
Saini P, Gayen P, Kumar D, Nayak A, Mukherjee N, Mukherjee S, Pal BC, Babu SPS. Antifilarial effect of ursolic acid from Nyctanthes arbortristis: molecular and biochemical evidences. Parasitol Int 2014; 63:717-28. [PMID: 25009078 DOI: 10.1016/j.parint.2014.06.008] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2013] [Revised: 06/23/2014] [Accepted: 06/26/2014] [Indexed: 10/25/2022]
Abstract
A bio-assay guided fractionation and purification approach was used to examine in vitro antifilarial activities of the crude methanolic extract of Nyctanthes arbortristis as well as fractions and isolated compound. From ethyl-acetate fraction we isolated and identified a triterpenoid compound which has been characterized as ursolic acid (UA) by HPLC and NMR data. We are reporting for the first time isolation and identification of UA from the leaves of N. arbortristis. The crude extract and UA showed significant micro- as well as macrofilaricidal activities against the oocyte, microfilaria and adult of Setaria cervi (S. cervi) by dye exclusion test and MTT reduction assay. Significant microfilaricidal activity of UA was further proved against mf of W. bancrofti by viability assay. The findings thus provide a new lead for development of a suitable filaricide from natural products. The molecular mechanism of UA was investigated by performing TUNEL, Hoechst staining, Annexin V-Cy3, flow cytometric analysis and DNA fragmentation assay. Differential expressions of pro- and anti-apoptotic genes were observed at the transcription and translational levels in a dose-dependent manner. Depletion in the worm GSH level and elevation in the parasite GST, SOD and super oxide anion indicated the generation of ROS. In this investigation we are reporting for the first time that UA acts its antifilarial effect through induction of apoptosis and by downregulating and altering the level of some key antioxidants like GSH, GST and SOD of S. cervi.
Collapse
Affiliation(s)
- Prasanta Saini
- Parasitology Laboratory, Department of Zoology, Centre for Advanced Studies, Visva-Bharati University, Santiniketan 731235, West Bengal, India
| | - Prajna Gayen
- Parasitology Laboratory, Department of Zoology, Centre for Advanced Studies, Visva-Bharati University, Santiniketan 731235, West Bengal, India
| | - Deepak Kumar
- National Institute of Pharmaceutical Education and Research (NIPER), 4, Raja S.C. Mullick Road, Jadavpur, Kolkata 700032, West Bengal, India
| | - Ananya Nayak
- Parasitology Laboratory, Department of Zoology, Centre for Advanced Studies, Visva-Bharati University, Santiniketan 731235, West Bengal, India
| | - Niladri Mukherjee
- Parasitology Laboratory, Department of Zoology, Centre for Advanced Studies, Visva-Bharati University, Santiniketan 731235, West Bengal, India
| | - Suprabhat Mukherjee
- Parasitology Laboratory, Department of Zoology, Centre for Advanced Studies, Visva-Bharati University, Santiniketan 731235, West Bengal, India
| | - Bikas C Pal
- National Institute of Pharmaceutical Education and Research (NIPER), 4, Raja S.C. Mullick Road, Jadavpur, Kolkata 700032, West Bengal, India
| | - Santi P Sinha Babu
- Parasitology Laboratory, Department of Zoology, Centre for Advanced Studies, Visva-Bharati University, Santiniketan 731235, West Bengal, India.
| |
Collapse
|
34
|
Boureé P. [Treatment of lymphatic filariasis by a double dose]. Med Sante Trop 2014; 24:254-255. [PMID: 25580494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
|
35
|
Sharma OP, Vadlamudi Y, Kota AG, Sinha VK, Kumar MS. Drug targets for lymphatic filariasis: a bioinformatics approach. J Vector Borne Dis 2013; 50:155-162. [PMID: 24220073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023] Open
Abstract
This review article discusses the current scenario of the national and international burden due to lymphatic filariasis (LF) and describes the active elimination programmes for LF and their achievements to eradicate this most debilitating disease from the earth. Since, bioinformatics is a rapidly growing field of biological study, and it has an increasingly significant role in various fields of biology. We have reviewed its leading involvement in the filarial research using different approaches of bioinformatics and have summarized available existing drugs and their targets to re-examine and to keep away from the resisting conditions. Moreover, some of the novel drug targets have been assembled for further study to design fresh and better pharmacological therapeutics. Various bioinformatics-based web resources, and databases have been discussed, which may enrich the filarial research.
Collapse
Affiliation(s)
- Om Prakash Sharma
- Centre for Bioinformatics, School of Life Science, Pondicherry University, Puducherry, India
| | | | | | | | | |
Collapse
|
36
|
Ramaiah KD, Vanamail P, Pani SP, Das PK. The prevalences ofWuchereria bancroftiantigenaemia in communities given six rounds of treatment with diethylcarbamazine, ivermectin or placebo tablets. Annals of Tropical Medicine & Parasitology 2013; 97:737-41. [PMID: 14613632 DOI: 10.1179/000349803225001553] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
The ICT filariasis card test was used to determine the prevalences of Wuchereria bancrofti antigenaemia among villagers in India. Prior to the tests, those living in the 15 study villages had been treated six times, in six rounds of mass treatment (with 54%-75% coverage) spread over 6 years, with single doses of diethylcarbamazine (five villages), ivermectin (five villages) or placebo (five villages). The corresponding overall prevalences (and ranges) of filarial antigenaemia were 20.2% (13.7%-28.6%), 22.6% (15.3%-34.3%) and 25.9% (22.6%-29.3%), respectively. The overall prevalence of antigenaemia in the villages where diethylcarbamazine (DEC) had been distributed (but not that in the 'ivermectin' villages) was significantly lower than that recorded in the 'placebo' villages (z =2.56; P <0.05). The prevalences of antigenaemia among the villagers aged 1-5 years (18.9%, 15.6% and 22.4% in the DEC, ivermectin and placebo villages, respectively) did not differ significantly with treatment (P >0.05). The results indicate that annual mass treatments based on DEC or ivermectin, with 54%-75% treatment coverage, may have only a limited effect on the prevalence of infection with adult W. bancrofti. The possible reasons for the antigenaemias observed are discussed.
Collapse
Affiliation(s)
- K D Ramaiah
- Vector Control Research Centre (Indian Council of Medical Research), Medical Complex, Indira Nagar, Pondicherry--605 006, India.
| | | | | | | |
Collapse
|
37
|
Graves PM, Makita L, Susapu M, Brady MA, Melrose W, Capuano C, Zhang Z, Dapeng L, Ozaki M, Reeve D, Ichimori K, Kazadi WM, Michna F, Bockarie MJ, Kelly-Hope LA. Lymphatic filariasis in Papua New Guinea: distribution at district level and impact of mass drug administration, 1980 to 2011. Parasit Vectors 2013; 6:7. [PMID: 23311302 PMCID: PMC3606332 DOI: 10.1186/1756-3305-6-7] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2012] [Accepted: 12/23/2012] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Lymphatic filariasis (LF) caused by Wuchereria bancrofti is present at high prevalence in some parts of Papua New Guinea. However, there has been no rigorous data-based representative assessment of nationwide prevalence of LF. The LF programme has been daunted by the scope of the problem, and progress on mass drug administration (MDA) has been slow and lacking in resources. METHODS A systematic literature review identified LF surveys in Papua New Guinea between 1980 and 2011. Results were extracted by location, time period and test used (blood slide, immunochromatographic test (ICT) or Og4C3 ELISA) and combined by district. Three criteria schemes based on the Global Programme to Eliminate Lymphatic Filariasis guidelines, with modifications, were developed to classify and prioritize districts by prevalence level. Results of repeated surveys in the same sites were used to investigate the impact of MDA on LF prevalence over the time period. RESULTS There were 312 distinct survey sites identified in 80 of the 89 districts over the 31-year period. The overall LF prevalence in the sites tested was estimated at 18.5 to 27.5% by blood slide for microfilariae (Mf), 10.1% to 12.9% by ICT and 45.4% to 48.8% by Og4C3. Biases in site selection towards areas with LF, and change in type of assay used, affected the prevalence estimates, but overall decline in prevalence over the time period was observed. Depending on the criteria used, 34 to 36 districts (population 2.7 to 2.9 million) were classed as high endemic (≥5% prevalence), 15 to 25 districts (1.7 to 1.9 million) as low endemic (<5%) and 20 to 31 (1.3 to 2.2 million) as non-endemic. Nine districts (0.7 million) had no information. The strong impact of MDA, especially on microfilaria (Mf) prevalence, was noted in sites with repeat surveys. CONCLUSIONS This analytical review of past surveys of LF in Papua New Guinea enables better estimation of the national burden, identifies gaps in knowledge, quantifies and locates the population at risk, and can be used to predict the likely impact of MDA and/or vector control. Better targeting of districts by level of prevalence will strengthen the control programme, facilitate monitoring of the disease trend and increase the likelihood of reaching the target of LF elimination by 2020.
Collapse
Affiliation(s)
- Patricia M Graves
- Department of Public Health, Tropical Medicine and Rehabilitation Sciences, James Cook University, Cairns and Townsville, Queensland, Australia
- James Cook University, PO Box 6811, Cairns, Queensland, 4870, Australia
| | - Leo Makita
- Department of Health, Port Moresby, Papua New Guinea
| | - Melinda Susapu
- Department of Health, Port Moresby, Papua New Guinea
- WHO, Port Moresby, Papua New Guinea
| | - Molly A Brady
- Current address: WHO, Regional Office for the Western Pacific, Manila, Philippines
| | - Wayne Melrose
- Department of Public Health, Tropical Medicine and Rehabilitation Sciences, James Cook University, Cairns and Townsville, Queensland, Australia
| | - Corinne Capuano
- Current address: WHO, Regional Office for the Western Pacific, Manila, Philippines
| | | | | | - Masayo Ozaki
- WHO, Pacific Programme to Eliminate Lymphatic Filariasis (PacELF), Suva, Republic of Fiji
- Current address: University of Alabama School of Medicine, Birmingham, Alabama, USA
| | - David Reeve
- Department of Public Health, Tropical Medicine and Rehabilitation Sciences, James Cook University, Cairns and Townsville, Queensland, Australia
| | | | | | - Frederick Michna
- Department of Public Health, Tropical Medicine and Rehabilitation Sciences, James Cook University, Cairns and Townsville, Queensland, Australia
| | - Moses J Bockarie
- Liverpool School of Tropical Medicine (LSTM), Centre for Neglected Tropical Diseases, Liverpool, United Kingdom of Great Britain and Northern Ireland
| | - Louise A Kelly-Hope
- Liverpool School of Tropical Medicine (LSTM), Centre for Neglected Tropical Diseases, Liverpool, United Kingdom of Great Britain and Northern Ireland
| |
Collapse
|
38
|
Affiliation(s)
- David H Molyneux
- Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| |
Collapse
|
39
|
Satimai W, Jiraamonnimit C, Thammapalo S, Choochote W, Luenee P, Boitano JJ, Wongkamchai S. The impact of a national program to eliminate lymphatic filariasis in selected Myanmar immigrant communities in Bangkok and Ranong Province, Thailand. Southeast Asian J Trop Med Public Health 2011; 42:1054-1064. [PMID: 22299429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Some immigrants from Myanmar to Thailand have brought Wuchereria bancrofti infections with them, causing a community health problem for Thai citizens. The seroprevalence of bancroftian filariasis was detected in 438 and 512 Myanmar immigrants residing in Bangkok and Ranong Provinces, respectively, along with 81 Thai citizens living in Bangkok. The immunochromatograpy card test was positive in 5 Myanmar immigrants living in Bangkok and 1 living in Ranong for a prevalence of 0.63%. Antifilarial IgG4 antibodies were found in 21 Myanmar immigrants living in Bangkok and 14 living in Ranong for a prevalence of 3.68%. None of the samples from Thai citizens were positive with either test. These prevalence rates are lower than those observed between 2001 and 2005. The Thai mass drug administration program to eliminate lymphatic filariasis among Myanmar immigrants appears to be a successful public health strategy.
Collapse
Affiliation(s)
- Wichai Satimai
- Bureau of Vector-Borne Disease, Department of Disease Control, Nonthaburi, Bangkok, Thailand
| | | | | | | | | | | | | |
Collapse
|
40
|
Wamae CN, Njenga SM, Ngugi BM, Mbui J, Njaanake HK. Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Trop 2011; 120 Suppl 1:S33-8. [PMID: 20933491 DOI: 10.1016/j.actatropica.2010.09.009] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2009] [Revised: 06/24/2010] [Accepted: 09/17/2010] [Indexed: 11/29/2022]
Abstract
OBJECTIVES To evaluate the effect of multiple rounds of annual single dose of DEC (6 mg/kg) or albendazole (400mg) given alone or in combination on Wuchereria bancrofti microfilaraemia, anti-filarial IgG1 and IgG4 and antigenaemia. METHODS A total of 170 participants were randomly assigned to albendazole (n = 62), DEC (n = 54), and DEC plus albendazole (DEC/ALB) combination (n = 54). Blood samples were collected at pre-treatment in 1998, at 1 week and 6 months after the first treatment and thereafter before subsequent treatments in 1999 and 2000. Effects of treatment on W. bancrofti infection were determined by changes in levels of microfilaraemia, antifilarial antibodies and circulating filarial antigen. RESULTS Comparison of geometric mean microfilariae intensities between DEC/ALB combination and DEC or albendazole single therapy groups after two rounds of annual treatment and 24 months follow-up showed that combination therapy resulted in a greater reduction of microfilaraemia than single therapy with either albendazole (p < 0.001) or DEC alone (p = 0.146). The overall levels of anti-filarial antibodies decreased significantly (p = 0.028 for IgG1 and p < 0.043 for IgG4) in all treatment groups at 24 months follow-up. Additionally, overall reduction in geometric mean circulating filarial antigen levels at 24 months was 44%, 60% and 85% for albendazole, DEC and DEC/ALB groups, respectively. CONCLUSIONS These study findings suggest that albendazole improved efficacy of DEC and mass administration of a combination of the two drugs would therefore enhance the interruption of transmission of W. bancrofti in endemic areas. This information has important implications for the ongoing Global Program for Elimination of Lymphatic Filariasis.
Collapse
Affiliation(s)
- C N Wamae
- Kenya Medical Research Institute, PO Box 54840-00200, Nairobi, Kenya.
| | | | | | | | | |
Collapse
|
41
|
King JD, Zielinski-Gutierrez E, Pa'au M, Lammie P. Improving community participation to eliminate lymphatic filariasis in American Samoa. Acta Trop 2011; 120 Suppl 1:S48-54. [PMID: 20932818 DOI: 10.1016/j.actatropica.2010.08.021] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2009] [Revised: 05/26/2010] [Accepted: 08/26/2010] [Indexed: 11/17/2022]
Abstract
In 2000, the American Samoa Department of Health initiated a campaign of annual mass drug administration (MDA) with albendazole and diethylcarbamazine (DEC) to eliminate transmission of filariasis. Drug coverage was well below prescribed targets in the first three campaigns, ranging from 24 to 52% of the total population. Evaluation findings from a variety of formative research methods identified opportunities to improve MDA coverage and ensuing program modifications resulted in increased drug coverage of 65-71% in the following four annual distributions. Partnering with churches for drug distribution and using multiple media channels for health promotion led to sustained program improvements. With the increased emphasis on the use of mass distribution for delivery of drugs for a number of neglected tropical diseases, other programs may benefit from a similar approach.
Collapse
Affiliation(s)
- Jonathan D King
- Division of Parasitic Diseases, Centers for Disease Control and Prevention, 4770 Buford Highway, Atlanta, GA 30341, United States.
| | | | | | | |
Collapse
|
42
|
Tisch DJ, Alexander NDE, Kiniboro B, Dagoro H, Siba PM, Bockarie MJ, Alpers MP, Kazura JW. Reduction in acute filariasis morbidity during a mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea. PLoS Negl Trop Dis 2011; 5:e1241. [PMID: 21765964 PMCID: PMC3134431 DOI: 10.1371/journal.pntd.0001241] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2010] [Accepted: 06/02/2011] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Acute painful swelling of the extremities and scrotum are debilitating clinical manifestations of Wuchereria bancrofti infection. The ongoing global program to eliminate filariasis using mass drug administration is expected to decrease this and other forms of filarial morbidity in the future by preventing establishment of new infections as a consequence of eliminating transmission by the mosquito vector. We examined whether mass treatment with anti-filarial drugs has a more immediate health benefit by monitoring acute filariasis morbidity in Papua New Guinean communities that participated in a 5-year mass drug administration trial. METHODOLOGY/PRINCIPAL FINDINGS Weekly active surveillance for acute filariasis morbidity defined by painful swelling of the extremities, scrotum and breast was performed 1 year before and each year after 4 annual mass administrations of anti-filarial drugs (16,480 person-years of observation). Acute morbidity events lasted <3 weeks in 92% of affected individuals and primarily involved the leg (74-79% of all annual events). The incidence for all communities considered together decreased from 0.39 per person-year in the pre-treatment year to 0.31, 0.15, 0.19 and 0.20 after each of 4 annual treatments (p<0.0001). Residents of communities with high pre-treatment transmission intensities (224-742 infective bites/person/year) experienced a greater reduction in acute morbidity (0.62 episodes per person-year pre-treatment vs. 0.30 in the 4(th) post-treatment year) than residents of communities with moderate pre-treatment transmission intensities (24-167 infective bites/person/year; 0.28 episodes per person-year pre-treatment vs. 0.16 in the 4(th) post-treatment year). CONCLUSIONS Mass administration of anti-filarial drugs results in immediate health benefit by decreasing the incidence of acute attacks of leg and arm swelling in people with pre-existing infection. Reduction in acute filariasis morbidity parallels decreased transmission intensity, suggesting that continuing exposure to infective mosquitoes is involved in the pathogenesis of acute filariasis morbidity.
Collapse
Affiliation(s)
- Daniel J. Tisch
- Case Western Reserve University, Cleveland, Ohio, United States of America
| | - Neal D. E. Alexander
- Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Benson Kiniboro
- Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
| | - Henry Dagoro
- Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
| | - Peter M. Siba
- Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
| | - Moses J. Bockarie
- Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
- Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - Michael P. Alpers
- Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
- Curtin University, Perth, Australia
| | - James W. Kazura
- Case Western Reserve University, Cleveland, Ohio, United States of America
- * E-mail:
| |
Collapse
|
43
|
Hoti SL, Pani SP, Vanamail P, Athisaya Mary K, Das LK, Das PK. Effect of a single dose of diethylcarbamazine, albendazole or both on the clearance of Wuchereria bancrofti microfilariae and antigenaemia among microfilaria carriers: a randomized trial. Natl Med J India 2010; 23:72-76. [PMID: 20925201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
BACKGROUND Lymphatic filariasis is a major vector-borne parasitic disease. The global programme to eliminate lymphatic filariasis was launched in 1997 and currently over 570 million people are covered under it in 48 countries. Mass annual single-dose drug administration of diethylcarbamazine (DEC), co-administrated with albendazole for 5-6 years and mass distribution of diethylcarbamazine-fortified salt are the two strategies for elimination of filariasis. METHODS Asymptomatic volunteers residing in Puducherry, India were screened for microfilaria (mf) by examining nocturnal thick blood smears. Those testing positive were randomly assigned to receive a single dose of DEC (6 mg/kg body weight) or albendazole 400 mg or both. Participants were hospitalized for 5 days. Membrane filtration count was used to assess microfilaraemia and ELISA (Og4C3) assay to measure circulating filarial antigens (CFA). Measurements were done before treatment and at 1, 2 and 3 years post-treatment. Viability of the adult worms was assessed by looking for the filarial dance sign (FDS) using ultrasound examination of the scrotum in men with hydrocele. RESULTS Fifty-four microfilaraemic Individuals were studied. The mf prevalence started decreasing only by day 180 posttreatment in the DEC group but much earlier in the other two groups (day 30 in the albendazole and day 90 in the DEC with albendazole group). The decrease in mfwas marginal (17.6%, 26.3% and 27.8%, respectively) by the end of year 1 posttreatment, but significant (96.7%, 78.6% and 93.3%, respectively) by the end of year 2 post-treatment (p < 0.05). By the end of year 3, the level decreased to 80% in the DEC, 90% in the albendazole and to 100% in the DEC and albendazole groups. However, the mf intensity decreased significantly (by 39%; p < 0.05) by day 7 post-treatment in both the DEC and DEC with albendazole groups, but only by day 30 in the albendazole group. In all the drug groups, the prevalence as well as intensity of CFA returned to pretreatment levels by the end of year 3 post-treatment. CONCLUSION Annual single-dose administration of all the 3 drug regimens significantly reduced antigenaemia levels. There were no significant differences in the efficacy and overall pattern of CFA clearance between the 3 drug regimens.
Collapse
Affiliation(s)
- S L Hoti
- Vector Control Research Centre, Department of Health Research (ICMR), Indira Nagar, Puducherry 605006, India.
| | | | | | | | | | | |
Collapse
|
44
|
Bhumiratana A, Pechgit P, Koyadun S, Siriaut C, Yongyuth P. Imported bancroftian filariasis: diethylcarbamazine response and benzimidazole susceptibility of Wuchereria bancrofti in dynamic cross-border migrant population targeted by the National Program to Eliminate Lymphatic Filariasis in South Thailand. Acta Trop 2010; 113:121-8. [PMID: 19835831 DOI: 10.1016/j.actatropica.2009.10.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2008] [Revised: 10/06/2009] [Accepted: 10/07/2009] [Indexed: 11/27/2022]
Abstract
The implementation on the Thailand-Myanmar border of annual mass drug administration (MDA) of a single 6 mg/kg dose of diethylcarbamazine (DEC) plus 400mg albendazole, part of the National Program to Eliminate Lymphatic Filariasis (PELF), has been challenging. In particular, chain migration of cross-border Myanmar workers at risk for nocturnally periodic Wuchereria bancrofti infection can lead to imported bancroftian filariasis (IBF) in Thailand. IBF is targeted for multiple-dose MDA with 300 mg DEC, in addition to what is recommended by the World Health Organization (WHO). The dynamic Myanmar migrants in Phang-nga, southern Thailand were sampled to test whether the responsible W. bancrofti has a genetic predisposition of benzimidazole exposure, and IBF exhibits DEC susceptibility. The long-term migrants had more access to DEC. IBF in W. bancrofti antigenemic (microfilaremic vs. amicrofilaremic) short-term migrants exhibited susceptibility to a 300-mg single-dose DEC treatment. During the course of a 3-month follow-up, antigenemia was significantly reduced, but microfilaremia was fluctuated. Surprisingly, a newly recognized Mansonella infection co-existing among W. bancrofti-affected Myanmar migrants elicited microfilaremia clearance within a month after treatment. As a result of the presence of genetically stable W. bancrofti beta-tubulin (Wbtubb) gene responsible for benzimidazole susceptibility, IBF did not possess a genetic predisposition for benzimidazole exposure. Point mutations at positions Phe167Tyr and Phe200Tyr were not detected by Wbtubb locus-specific nested PCR and sequencing. This study has the potential to help guide not only the Thai/Myanmar PELF surveillance and monitoring of mass treatment impacts on W. bancrofti, but also the other endemic countries allied with the Global Program to Eliminate Lymphatic Filariasis (GPELF).
Collapse
Affiliation(s)
- A Bhumiratana
- Department of Parasitology and Entomology, Faculty of Public Health, Mahidol University, Bangkok 10400, Thailand.
| | | | | | | | | |
Collapse
|
45
|
Hoti SL, Dhamodharan R, Subramaniyan K, Das PK. An allele specific PCR assay for screening for drug resistance among Wuchereria bancrofti populations in India. Indian J Med Res 2009; 130:193-199. [PMID: 19797818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023] Open
Abstract
BACKGROUND & OBJECTIVE Albendazole, a commonly used anthelminthic drug that targets the polymerization of alpha- and beta-tubulin dimer is currently co-administered with the antifilarial drug, diethylcarbamazine citrate (DEC) in the ongoing Global Programme for Elimination of Lymphatic Filariasis (GPELF). The experience in veterinary field has shown that there can be a rapid development of resistance to this drug, which therefore, needs to be monitored regularly in GPELF. Hence, we investigated the nucleotide polymorphism in the albendazole-binding domain of the isotype 1 beta-tubulin gene from several populations of Wuchereria bancrofti and developed an AS-PCR assay useful in screening for sensitive/resistance alleles among parasite populations and also evaluated its utility. METHODS For studying the polymorphism of isotype 1 beta-tubulin gene, a 475 bp fragment spanning exon 5 and 6 of the gene was amplified and sequenced from the genomic DNA of W. bancrofti collected from six geographic regions of India. An allele specific (AS) PCR for screening albendazole sensitivity/resistance was developed and a total of 55 mf samples from blood smears on slides collected from Thiruvannamalai, Thanjavur and Puducherry were screened. Selective therapy with DEC was in place in three areas, mass drug administration (MDA) with DEC alone was implemented in four areas, while DEC plus albendazole was administered in one district. RESULTS The analysis of the nucleotide sequence of the fragment from 20 W. bancrofti populations showed the domain to be highly conserved. An allele-specific PCR assay developed was used to detect sensitive/resistance alleles among 55 isolates of W. bancrofti and no albendazole resistance alleles were detected among the populations tested. INTERPRETATION & CONCLUSION The drug-binding domain of isotype 1 beta-tubulin gene of W. bancrofti from different geographical locations was highly conserved. The AS-PCR developed showed potential application as a tool for monitoring albendazole sensitivity/resistance alleles among W. bancrofti populations, in areas where combination therapy of DEC-albendazole is being mass administered in the LF elimination programme.
Collapse
Affiliation(s)
- S L Hoti
- Vector Control Research Centre (ICMR), Puducherry, India.
| | | | | | | |
Collapse
|
46
|
Alves LC, Cavalcanti MGS, Araújo HRC, Silva GM, Veras DL, Paiva MHS, Brayner FA. Ultrastructural analysis of microfilariae of Wuchereria bancrofti obtained from persistent carriers after repeated courses of diethylcarbamazine. Micron 2009; 40:659-64. [PMID: 19359187 DOI: 10.1016/j.micron.2009.01.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2007] [Revised: 01/13/2009] [Accepted: 01/15/2009] [Indexed: 11/18/2022]
Abstract
Single dose of diethylcarbamazine (DEC) used in control programs is effective in breaking the transmission of filariasis. In order to investigate the effect of aggressive therapy on Wuchereria bancrofti (Wb) microfilariae, DEC was given to 29 patients who were positive for the circulating filarial antigen (CFA) assay but did not have clinical manifestations of filariasis, at 6 mg/kg/day for 12 days and again six months later using the same dosing regimen. For each patient, microfilarial density and serum CFA were followed up for two years. Ultrastructural analyses on Wb microfilariae obtained after repeated treatment with DEC were also performed. Microfilaremia and antigenemia decreased significantly after 12 months but returned to the initial levels after 24 months. This could indicate, as shown by other authors, that aggressive repeated therapy with DEC alone is ineffective in eradicating adult W. bancrofti, particularly in infected but asymptomatic individuals. The objective of the present study was to analyze the microfilaremic and antigenemic behavior and ultrastructural changes caused by different DEC concentrations in vitro in Wb microfilariae obtained from individuals who were sensitive and refractory to treatment. After in vitro treatment of the microfilariae using 5 and 10 microg/ml of DEC for 1h, ultrastructural analysis revealed low levels of cell damage compared with embryos obtained from individuals from a different area who had never received DEC treatment before. The results obtained suggest that microfilariae from patients who receive repeated aggressive therapy are less sensitive to DEC in vitro.
Collapse
Affiliation(s)
- L C Alves
- Departamento de Parasitologia, Centro de Pesquisas Aggeu Magalhães (FIOCRUZ), Recife, PE, Brazil.
| | | | | | | | | | | | | |
Collapse
|
47
|
Dixit V, Gupta AK, Prasad GBKS. Interruption of annual single dose DEC regimen administration: impact on Wuchereria bancrofti microfilaraemia, vector infection and infectivity rates. J Commun Dis 2009; 41:25-31. [PMID: 19886172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
The effect of single dose diethylcarbamazine regimen (6 mg/kg body wt.) in comparison to standard DEC regimen i.e; 72 mg/kg body wt (administered in 12 consecutive days) in clearing Wuchereria bancrofti microfilariae from low density micro filariae carriers (1- 8 mf per 20 microl) and its impact on vector infection rate were studied in an urban region endemic for bancroftian filariasis. The efficacy of DEC regimens were determined by assessing the rate of successful treatment, percentage cure rate and percentage decrease in microfilariae count in treated subjects. The 12 days regimen was found very effective with 100% cure rate even after 4 years of drug therapy. In subjects, who received single dose DEC regimen, the rate of successful treatment, cure rate and percent decrease in micro filariae count was significantly low when assessed 24 hour after therapy. Reexamination of subjects in this group at 6,12, 24 and 48 months after therapy showed a sharp decline in all therapeutic indices and the microfilariae count reached pretreatment levels by 4th year of drug therapy. The single dose regimen had a marginal impact on vector infection and infectivity rates in Culex quinquefasciatus. A marked increase of vector infection and infectivity rates in parallel to human microfilaraemia rate was recorded from the same households when examined after 4th yr after therapy. Thus the single dose 6 mg/kg body wt. DEC regimen (administered only once) failed to clear microfilariae even in a situation of filarial low endemicity and did not influence the transmission potential of C. quinquefasciatus.
Collapse
Affiliation(s)
- Vandana Dixit
- School of Life Sciences, Pt. Ravishankar Shukla University, Raipur-492010, Chattisgarh, India
| | | | | |
Collapse
|
48
|
Hoti SL, Sharma R, Mary KA, Dhamodharan R, Krishnamoorthy K, Das PK. A method for detecting microfilaraemia, filarial specific antigens and antibodies and typing of parasites for drug resistance and genotypes using finger prick blood sample. Acta Trop 2008; 107:268-71. [PMID: 18771650 DOI: 10.1016/j.actatropica.2008.07.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2007] [Revised: 07/25/2008] [Accepted: 07/26/2008] [Indexed: 11/29/2022]
Abstract
Monitoring and evaluation of programme to eliminate lymphatic filariasis (LF) depends on epidemiological assessment using appropriate indicators. Minimum efforts using reliable tests are necessary to guide the programme managers in decision-making. Impact of Mass Drug Administration (MDA) towards filariasis elimination can be assessed by the detection of microfilariae (mf) or parasite DNA (infective), filarial antigens (infected) and antibodies (exposure). It is also important to monitor drug resistance and variation in genetic structure of parasite populations using molecular markers. We developed a method to carry out parasitological, molecular, immunological and genetic analysis from a minimum volume of blood sample (about 150 microl) drawn from finger tip of an individual residing in LF endemic area. The method involves separation of sera for immunological assays and isolation of mf of Wuchereria bancrofti from the blood clots for counting, which were then used for W. bancrofti specific PCR, screening for albendazole sensitivity/resistance alleles by AS-PCR, RAPD profiling and ITS 2 PCR for genotyping. A protocol is also suggested for the separation of sera for assays to detect antigen and antibodies and isolation of mf from clots for genetic analysis. The protocol developed has shown potential application in monitoring several immunological, parasitological and molecular parameters from a limited amount of blood sample collected by finger prick, in large-scale operations.
Collapse
Affiliation(s)
- S L Hoti
- Vector Control Research Centre, Indian Council of Medical Research (DHR), Indira Nagar, Puducherry 605006, India.
| | | | | | | | | | | |
Collapse
|
49
|
Abstract
A 5-year study was conducted with 200 selected microfilaremic subjects bearing Mean microfilarial density (MMD) of 11.6 from 16 small foothill villages around Susunia Hill, Bankura, West Bengal during June 2001 to May 2002. All of them were treated with a single dose (6 mg/kg body weight) to triple dose diethylcarbamazine (DEC). On day 180, 365, 730, 1,095, 1,460, and 1,825, recurrence of microfilaremia were 0.0%, 6.0%, 15.5% (6 + 9.5), 27% (15.5 + 11.5), 42% (27 + 15), and 49% (42 + 7), respectively, and corresponding MMD were 0.0, 1.2, 1.4, 2.7, 6.2, and 7.8, respectively. Culex quinquefasciatus was incriminated as the vector and their infection and infectivity rates reduced to 4.2% and 0.81% from the initial values of 6.40% and 1.33%, respectively, after DEC treatment to selected mff carriers. Single-dose DEC treatment was found effective for reduction of microfilaremia and MMD but it was not always sufficient to eliminate all the microfilariae, especially when MMD was high (>40). For microfilaremics with high MMD, a single course (6 mg/kg body weight for 3 days) DEC treatment may be safe for the first instance.
Collapse
Affiliation(s)
- Goutam Chandra
- Department of Zoology, Mosquito and Microbiology Research Units, Parasitology Laboratory, The University of Burdwan, West Bengal, India.
| | | |
Collapse
|
50
|
Showkath AMK, Regu K, Rajendran R, Mohanan MK, Ganesh B. Awareness of health personnel about lymphatic filariasis and mass drug administration in Kerala State. J Commun Dis 2008; 40:37-40. [PMID: 19127667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
The mass drug administration programme to eliminate lymphatic filariasis with DEC in Kerala was started in 1997, extended to all the 11 endemic districts by 2005. Since the beginning of Mass drug Administration, the drug consumption rate was found to be not satisfactory. The reasons for noncompliance indicated that the community is not fully convinced about the programme. The knowledge of the medical and para medical workers is certainly a factor in the success of implementation of the programme and is vital. To ascertain the knowledge, a study was undertaken and found not satisfactory. Hence intensive training on all aspects of lymphatic filariasis and the Mass drug Administration programme to achieve the requisite drug consumption rate to meet the goal is needed.
Collapse
Affiliation(s)
- Ali M K Showkath
- Regional Filaria Training & Research Centre, Karaparamba, Kozhikode, Kerala.
| | | | | | | | | |
Collapse
|